{"text": "One trial is evaluating palbociclib in combination with letrozole and the other has paired the CDK-4/6 inhibitor with fulvestrant ( Faslodex ) , another type of estrogen suppressor .", "label": "", "metadata": {}, "score": "20.4407"}
{"text": "Brief Title ICMJE .Palbociclib ( PD-0332991 ) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure ( PALOMA-3 ) .", "label": "", "metadata": {}, "score": "24.043066"}
{"text": "\" The safety profile is acceptable and manageable with uncomplicated neutropenia as the most frequently reported adverse event .The results confirm the preclinical observations made with palbociclib in breast cancer models . \" A separate preliminary study involving a different CDK-4/6 inhibitor demonstrated activity in 47 patients with metastatic breast cancer .", "label": "", "metadata": {}, "score": "24.56057"}
{"text": "Further , a small lead - in phase I study conducted prior to this phase II trial showed that palbociclib and the antiestrogen drug letrozole could be given safely as a combination , with manageable side effects and also showed preliminary signs of good efficacy .", "label": "", "metadata": {}, "score": "28.123514"}
{"text": "In vitro treatment of ER - positive breast cancer cell lines ; with the combination of palbociclib and antiestrogens leads to increased cell senescence , which was ; sustained for up to 6 days following drug removal .", "label": "", "metadata": {}, "score": "29.190655"}
{"text": "This is normal and is due to slight batch - to - batch variations .Palbociclib ( PD-0332991 ) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell - free assays , respectively .", "label": "", "metadata": {}, "score": "30.27459"}
{"text": "In vitro , palbociclib reduced ; cellular proliferation of estrogen receptor ( ER)-positive breast cancer cell lines by blocking progression ; of the cell from G1 into S phase of the cell cycle .", "label": "", "metadata": {}, "score": "30.334219"}
{"text": "Analysis of overall survival showed a 4-month improvement in the palbociclib group , but the difference from the letrozole - only group did not reach statistical significance , as reported here at the American Association for Cancer Research meeting .", "label": "", "metadata": {}, "score": "31.928274"}
{"text": "Multicenter , Randomized , Double - blind , Placebo - controlled , Phase 3 Trial Of Fulvestrant ( Faslodex ( Registered ) ) .With Or Without Pd-0332991 ( Palbociclib ) + /- Goserelin In Women With Hormone Receptor - positive , Her2-negative Metastatic Breast Cancer Whose Disease Progressed After Prior Endocrine Therapy .", "label": "", "metadata": {}, "score": "31.955648"}
{"text": "Preclinical studies identified luminal ER+ breast cancer cell lines with elevated expression of cyclin - D1 , Rb and reduced p16 expression as being associated with palbociclib sensitivity ( Finn et al .", "label": "", "metadata": {}, "score": "32.15686"}
{"text": "In addition , synergistic activity was seen in vitro when combined with tamoxifen .Methods : This Phase II trial was designed as a two - part study evaluating P+L in front - line ER+/HER2- metastatic breast cancer ( MBC ) .", "label": "", "metadata": {}, "score": "34.243557"}
{"text": "Selecting the optimal treatment for postmenopausal patients with hormone receptor - positive metastatic breast cancer remains a challenge .This decision was further complicated by a phase III trial conducted by SWOG that demonstrated an improvement in survival for the combination of anastrozole and fulvestrant .", "label": "", "metadata": {}, "score": "34.487103"}
{"text": "Inhibition of CDK-4/6 by palbociclib restores the normal cell - cycle process .The studies also suggested that combining palbociclib with a drug that inhibited or suppressed estrogen , such as tamoxifen or letrozole , resulted in synergistic cell - killing activity compared with either agent by itself .", "label": "", "metadata": {}, "score": "34.709724"}
{"text": "The progression - free survival results indicated a 51 percent reduction in the risk of disease progression with the addition of palbociclib to letrozole .The challenge with any targeted drug is identifying patients who are dependent on the target , \" said Finn . \"", "label": "", "metadata": {}, "score": "34.995728"}
{"text": "Palbociclib Results .The study by Finn 's group consisted of two phases .During the first phase , unselected postmenopausal women with metastatic luminal A breast cancer received letrozole with palbociclib or placebo .", "label": "", "metadata": {}, "score": "35.1152"}
{"text": "Articles related to Breast Cancer : .Modulation of Cyclins , p53 and Mitogen - Activated Protein Kinases Signaling in Breast Cancer Cell Lines by 4-(3,4,5-Trimethoxyphenoxy)benzoic Acid .", "label": "", "metadata": {}, "score": "35.776604"}
{"text": "In general , Rugo notes , she would rather enroll patients to the clinical trial exploring palbociclib with letrozole , rather than selecting whether to use fulvestrant , anastrozole , or the combination .", "label": "", "metadata": {}, "score": "36.060787"}
{"text": "In general , Rugo notes , she would rather enroll patients to the clinical trial exploring palbociclib with letrozole , rather than selecting whether to use fulvestrant , anastrozole , or the combination .", "label": "", "metadata": {}, "score": "36.060787"}
{"text": "A Phase III Randomized , Double Blind Placebo Controlled Study of BKM120 With Fulvestrant , in Postmenopausal Women With Hormone Receptor - positive HER2-negative Locally Advanced or Metastatic Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment .", "label": "", "metadata": {}, "score": "36.103622"}
{"text": "In addition , in vitro studies have shown that similar to trastuzumab , ado - trastuzumab ; emtansine inhibits HER2 receptor signaling , mediates antibody - dependent cell - mediated ; cytotoxicity and inhibits shedding of the HER2 extracellular domain in human breast cancer cells ; that overexpress HER2 .", "label": "", "metadata": {}, "score": "36.54252"}
{"text": "Overall , the ability of CDK2 and CDK4 to mediate various malignant phenotypes that play important roles in cancer biogenesis has prompted the development of CDK2 or CDK4 specific inhibitors .", "label": "", "metadata": {}, "score": "37.381405"}
{"text": "Detailed Description .PRIMARY OBJECTIVES : . I. To compare the effect , in terms of progression free survival , of the antiestrogen fulvestrant alone with fulvestrant administered in combination with the dual - kinase inhibitor lapatinib for postmenopausal women with estrogen receptor ( ER ) and/or progesterone receptor ( PgR ) positive advanced breast cancer .", "label": "", "metadata": {}, "score": "37.50865"}
{"text": "( D )The CDK4/6 inhibitor PD0332991 was added to cells stably expressing pLKO.1 ( 100 nM , 500 nM and 1000 nM for MCF10A , MDA - MB-231 and MDA - MB-468 , respectively ) and unirradiated ( 0 ) , irradiated at 2 or 4 Gy .", "label": "", "metadata": {}, "score": "37.813114"}
{"text": "Fulvestrant inhibited the growth of established ; MCF-7 xenografts and of tamoxifen - resistant breast tumor ; xenografts . ; Fulvestrant showed no agonist - type effects in in vivo ; uterotropic assays in immature or ovariectomized mice and ; rats .", "label": "", "metadata": {}, "score": "38.744747"}
{"text": "This setting enables direct comparison of IC50 values of PHA-848125 across the panel for evaluation of its biochemical profile .The cytotoxic effects of TMZ are also evaluated in combination with the MGMT inhibitor BG .", "label": "", "metadata": {}, "score": "39.118244"}
{"text": "Condition ICMJE .Metastatic Breast Cancer .Intervention ICMJE .Drug : Palbociclib .Palbociclib 125 mg / day orally continuously dosed for 3 weeks followed by 1 week off ; repeated at each subsequent cycle .", "label": "", "metadata": {}, "score": "39.368866"}
{"text": "This randomized phase III trial studies fulvestrant and lapatinib to see how well they work compared to fulvestrant and a placebo in treating postmenopausal women with stage III or stage IV breast cancer that is hormone receptor - positive .", "label": "", "metadata": {}, "score": "39.42801"}
{"text": "Palbociclib shows promising results in patients with hormone receptor - positive metastatic breast cancer .\" Medical News Today .MediLexicon , Intl ., 8 Apr. 2014 .", "label": "", "metadata": {}, "score": "39.69207"}
{"text": "In addition , in vitro studies showed that overexpressed cyclin D1 leads to resistance to antiestrogens [ 54 ] .In addition , chemical inhibition of CDK4 and CDK6 synergizes with Herceptin and tamoxifen treatments [ 64 ] .", "label": "", "metadata": {}, "score": "39.926254"}
{"text": "We are doing further phase III work with the drug , but the current data are as exciting as the initial studies we were involved in when testing Herceptin for HER2-positive breast cancers .", "label": "", "metadata": {}, "score": "40.032112"}
{"text": "We present data showing that knockdown of CDK4 , but not of CDK2 , imparts radiosensitivity to breast cancer cells and normal mammary epithelial cells by signaling an apoptotic program .", "label": "", "metadata": {}, "score": "40.101963"}
{"text": "[ Time Frame : Cycles 1 and 2 ] [ Designated as safety issue : No ] .Cmin for palbociclib , fulvestrant and goserelin ( if applicable ) .", "label": "", "metadata": {}, "score": "40.348648"}
{"text": "Showed that silencing CDK4 radiosensitized breast cancer cells .MKHP :Developed cell lines stably silenced for CDK4 and performed Western blots showing downregulation of CDK4 .", "label": "", "metadata": {}, "score": "40.448997"}
{"text": "In addition , pertuzumab mediates antibody - dependent cell - mediated cytotoxicity ( ADCC ) .While pertuzumab alone inhibited the proliferation of human tumor cells , the combination of pertuzumab and trastuzumab augmented anti - tumor activity in HER2-overexpressing xenograft models .", "label": "", "metadata": {}, "score": "40.55954"}
{"text": "It shows no activity against CDK1/2/5 , EGFR , FGFR , PDGFR , InsR , etc .Phase 3 .Features : Non - cytotoxic , and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment ( a chemotherapeutic used to treat many cancers ) .", "label": "", "metadata": {}, "score": "40.578255"}
{"text": "Because the breast cancer cell lines overexpressed cyclin D1 , and cyclin A protein levels were elevated following irradiation , we tested whether knockdowns of their respective kinase partners CDK4 and CDK2 might alter the relative radioresistance of various breast cancer cell lines .", "label": "", "metadata": {}, "score": "41.378662"}
{"text": "In addition , they first proposed that ectopic expression of cyclin D1 leads to increased radioresistance in breast cancer cells by enhancing DNA repair in the radioresistant cells , as downregulation of cyclin D1 in this system abrogated enhanced DNA repair , resulting in radiosensitivity .", "label": "", "metadata": {}, "score": "41.860558"}
{"text": "The CDK4/6 inhibitor PD0332991 ( Axon1505 ) was purchased from Axon Medchem .When indicated , ImageJ software was used to quantify protein levels of Western blots ( NIH ) .", "label": "", "metadata": {}, "score": "42.001877"}
{"text": "For example , knockdown of cyclin E synergizes with doxorubicin to enhance radioresistance in breast cancer cells lines [ 101 ] .Induction of cyclin A has previously been observed in cells treated with UV or irradiation [ 91 , 102 ] .", "label": "", "metadata": {}, "score": "42.88112"}
{"text": "Endocrine Therapy With or Without Inhibition of EGF and HER2 Growth Factor Receptors : A Randomized , Double - Blind , Placebo - Controlled Phase III Trial of Fulvestrant With or Without Lapatinib ( GW572016 ) for Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer .", "label": "", "metadata": {}, "score": "43.253223"}
{"text": "Cyclin - dependent kinase 4 ; 2 .Cyclin - dependent kinase 6 .Mechanism of Action : 13 Target : cyclin - dependent kinase ( CDK ) 4 and 6 Action : inhibitor FDA : Palbociclib is an inhibitor of cyclin - dependent kinase ( CDK ) 4 and 6 .", "label": "", "metadata": {}, "score": "43.350044"}
{"text": "APA American Association for Cancer Research .( 2014 , April 8) . \"Palbociclib shows promising results in patients with hormone receptor - positive metastatic breast cancer .", "label": "", "metadata": {}, "score": "43.54286"}
{"text": "The investigators randomly assigned patients in each part in a ratio of 1:1 to either receive palbociclib plus letrozole , or letrozole alone .Patients continued to receive medication until disease progression , unacceptable toxicity , or withdrawal from the study , and their tumors were assessed every two months .", "label": "", "metadata": {}, "score": "43.832157"}
{"text": "In addition , breast tumors can acquire radioresistance [ 21 , 22 ] .Finding agents that sensitize malignant cells to radiation would increase tumor response while minimizing toxicity to surrounding organs by lowering effective therapeutic doses .", "label": "", "metadata": {}, "score": "43.88368"}
{"text": "Several studies have shown that G1/S phase regulatory molecules may drive lower survival rates in patients and resistance to adjuvant therapies .Deregulated expression of cell cycle molecules that specifically modulate CDK2 kinase activity has been associated with poor prognosis of breast cancer patients .", "label": "", "metadata": {}, "score": "43.92531"}
{"text": "Original Other Outcome Measures ICMJE .Not Provided .Descriptive Information .Brief Title ICMJE .Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor - Positive .", "label": "", "metadata": {}, "score": "44.93002"}
{"text": "In contrast , all cell lines harboring CDK4 knockdown , including ER - PR - HER2 + , ER - PR - HER2- , and MCF10A showed significantly decreased IC 50 , meaning that the ablation of CDK4 in both the normal and tumor cell lines sensitizes these cells to radiation .", "label": "", "metadata": {}, "score": "45.013046"}
{"text": "The safety between the two treatment arms will also be compared .During study treatment , pre- and perimenopausal women must be receiving therapy with the LHRH agonist goserelin ( Zoladex \u00ae or generic ) .", "label": "", "metadata": {}, "score": "45.111244"}
{"text": "The views expressed in this video are those of the panelists and do not necessarily reflect the opinion or policy of OncLiveTV Peer Exchange .PHA-848125 inhibits , although with lower potency , the activities of cyclin H / CDK7 , cyclin D1/CDK4 , p35/CDK5 , as well as cyclin E / CDK2 and cyclin B / CDK1 with IC50 values of 0.15 , 0.16 , 0.265 , 0.363 , 0.398 \u03bcM , respectively .", "label": "", "metadata": {}, "score": "45.318504"}
{"text": "In contrast , co - inhibition of CDK4 and CDK6 using a chemical inhibitor interferes with the cell cycle , leading to protection against chemotherapy [ 99 , 100 ] .", "label": "", "metadata": {}, "score": "45.36267"}
{"text": "\" Given the opportunity to question biomarkers prospectively , cyclin - D1 and p16 were hypothesized that they might improve on ER positivity alone .I 'm not necessarily surprised that it did n't perform better in part two than in part one .", "label": "", "metadata": {}, "score": "45.60113"}
{"text": "It significantly lowers serum ; estradiol concentrations and has no detectable effect on formation of adrenal corticosteroids ; or aldosterone .Malady that Drug Treats : advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy .", "label": "", "metadata": {}, "score": "45.842785"}
{"text": "These results demonstrate that knockdown of CDK4 and chemical inhibition of CDK4/CDK6 lead to different outcomes , as the inhibitor is protective of apoptosis in irradiated MCF10A and MDA - MB-231 cells , while promoting apoptosis in MDA - MB-468 cells .", "label": "", "metadata": {}, "score": "45.86441"}
{"text": "Title : Final results of a randomized Phase II study of PD 0332991 , a cyclin - dependent kinase ( CDK)-4/6 inhibitor , in combination with letrozole vs letrozole alone for first - line treatment of ER+/HER2- advanced breast cancer ( PALOMA-1 ; TRIO-18 ) .", "label": "", "metadata": {}, "score": "45.983162"}
{"text": "Instead , she believes the standard of care should be the 500 mg dose of fulvestrant alone .Andrew D. Seidman , MD , adds that men with ER - positive , tamoxifen refractory metastatic breast cancer also respond well to treatment with fulvestrant , further indicating that it should be a preferred first - line treatment .", "label": "", "metadata": {}, "score": "45.99147"}
{"text": "Instead , she believes the standard of care should be the 500 mg dose of fulvestrant alone .Andrew D. Seidman , MD , adds that men with ER - positive , tamoxifen refractory metastatic breast cancer also respond well to treatment with fulvestrant , further indicating that it should be a preferred first - line treatment .", "label": "", "metadata": {}, "score": "45.99147"}
{"text": "Primary Purpose : Treatment .Official Title : .A Phase II , Double - Blind , Placebo Controlled , Randomized Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy .", "label": "", "metadata": {}, "score": "46.322002"}
{"text": "( A )The figure shows colony formation in MCF10A and ER - PR - HER2- cells at 0 and 6 Gy .( B ) Survival curves of various cells transfected with pLKO.1 , shCDK2 or shCDK4 .", "label": "", "metadata": {}, "score": "46.380177"}
{"text": "Cells stably expressing pLKO.1 , shCDK2 or shCDK4 were irradiated at single doses of 0 , 1 , 2 , 4 , 6 , or 8 Gy \u03b3 - rays .", "label": "", "metadata": {}, "score": "46.487236"}
{"text": "DrugBank Targets : - .Mechanism of Action : 13 Target : malignant cells Action : accumulates FDA : The mechanism of Tc99 m Sestanibi localization in various types of breast tissue ( e.g. beinign , inflammatory , malignant , fiborous ) has not been established .", "label": "", "metadata": {}, "score": "46.588486"}
{"text": "Based on the SWOG and other trials , O'Shaughnessy now preferentially administers the 500 mg dose of fulvestrant in the first - line setting for tamoxifen - naive patients .", "label": "", "metadata": {}, "score": "46.68802"}
{"text": "Based on the SWOG and other trials , O'Shaughnessy now preferentially administers the 500 mg dose of fulvestrant in the first - line setting for tamoxifen - naive patients .", "label": "", "metadata": {}, "score": "46.68802"}
{"text": "Methods .To address whether deregulation of the G1 phase regulatory machinery contributes to radiotherapy resistance , the MCF10A immortalized human mammary epithelial cell line , ER - PR - Her2 + and ER - PR - Her2- breast cancer cell lines were irradiated .", "label": "", "metadata": {}, "score": "46.846645"}
{"text": "A patient who received adjuvant tamoxifen , and then a nonsteroidal aromatase inhibitor and subsequently megesterol acetate for advanced breast cancer is not eligible .Patients must have had prior treatment in either the adjuvant or metastatic setting with a commercially available third - generation aromatase inhibitor ( i.e. anastrozole , exemestane , or letrozole ) ; it is not required that tumors be resistant to such therapies .", "label": "", "metadata": {}, "score": "47.187843"}
{"text": "Similar to cyclins E and A , there is experimental evidence as to the involvement of cyclin D in resistance or sensitivity to various therapies .", "label": "", "metadata": {}, "score": "47.26174"}
{"text": "This demonstrates that CDK4 silencing does not radiosensitize cells by causing accumulation of cells in mitosis .Table 4 .Comparison of phospho - Histone 3 between control ( pLKO.1 ) and treatment ( shCDK4 ) groups .", "label": "", "metadata": {}, "score": "47.4758"}
{"text": "In cytosols derived from human breast adenocarcinomas , tamoxifen competes with estradiol for ; estrogen receptor protein .Malady that Drug Treats : HER2 + metastatic breast cancer .", "label": "", "metadata": {}, "score": "47.605843"}
{"text": "[ 2 ] A drug combination of TMZ , BG and PHA-848125 induces an additive or synergistic effect on cell growth , depending on the cell line .", "label": "", "metadata": {}, "score": "47.62963"}
{"text": "10.1002/ijc.10151 PubMed View Article .Poikonen P , Sjostrom J , Amini RM , Villman K , Ahlgren J , Blomqvist C : Cyclin A as a marker for prognosis and chemotherapy response in advanced breast cancer .", "label": "", "metadata": {}, "score": "47.803913"}
{"text": "To identify mechanisms resulting in radioresistance , we assessed the relative protein expression of G1/S cell cycle regulatory molecules that have been shown to associate with relapse and to impaired responses to various therapies .", "label": "", "metadata": {}, "score": "47.993523"}
{"text": "This method has been successfully used to detect phosphorylation of CDK2 or CDK4 targets , including NPM [ 73 , 76 , 77 ] .There were no significant changes in the levels of Bcl-2 ( ser70 ) or Mcl-1 ( ser159/thr163 ) , or in the total levels of those proteins .", "label": "", "metadata": {}, "score": "48.013657"}
{"text": "Epub 2011 .Potemski P , Kusinska R , Pasz - Walczak G , Piekarski JH , Watala C , Pluciennik E , Bednarek AK , Kordek R : Prognostic relevance of cyclin E expression in operable breast cancer .", "label": "", "metadata": {}, "score": "48.10444"}
{"text": "It shows little effect on CDK4/6 .Phase 2 .Recently Viewed Items .Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor ( BELLE-2 ) .", "label": "", "metadata": {}, "score": "48.183144"}
{"text": "10.1083/jcb.146.5.905 PubMed Central PubMed View Article .Mah LJ , Orlowski C , Ververis K , Vasireddy RS , El - Osta A , Karagiannis TC : Evaluation of the efficacy of radiation - modifying compounds using gammaH2AX as a molecular marker of DNA double - strand breaks .", "label": "", "metadata": {}, "score": "48.314537"}
{"text": "10.1038/modpathol.3800621 PubMed View Article .Jirstrom K , Stendahl M , Ryden L , Kronblad A , Bendahl PO , Stal O , Landberg G : Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification .", "label": "", "metadata": {}, "score": "48.387672"}
{"text": "Dean JL , Thangavel C , McClendon AK , Reed CA , Knudsen ES : Therapeutic CDK4/6 inhibition in breast cancer : key mechanisms of response and failure .", "label": "", "metadata": {}, "score": "48.43702"}
{"text": "Unfortunately , we were unable to show that ectopic expression of PP2Ac radiosensitizes breast cancer cells , or that its inhibition modulates radiation induced apoptosis in breast cancer cells .", "label": "", "metadata": {}, "score": "48.487747"}
{"text": "Poly [ ADP - ribose ] polymerase 2 ; 3 .Poly [ ADP - ribose ] polymerase 3 .Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse ; xenograft models of human cancer both as monotherapy or following platinum - based chemotherapy .", "label": "", "metadata": {}, "score": "48.526203"}
{"text": "To define predictive markers of clinical activity among women receiving fulvestrant with or without lapatinib .III .IV .To serologically determine if HER2 extracellular domain ( ECD ) and EGFR ECD levels can identify patients with a greater likelihood of response and clinical benefit to fulvestrant with or without lapatinib .", "label": "", "metadata": {}, "score": "49.039894"}
{"text": "10.1038/onc.2008.265 PubMed View Article .Chang AR , Wu HG , Park CI , Jun YK , Kim CW : Expression of epidermal growth factor receptor and cyclin D1 in pretreatment biopsies as a predictive factor of radiotherapy efficacy in early glottic cancer .", "label": "", "metadata": {}, "score": "49.157085"}
{"text": "10.1002/hed.20788 PubMed View Article .Higuchi E , Oridate N , Homma A , Suzuki F , Atago Y , Nagahashi T , Furuta Y , Fukuda S : Prognostic significance of cyclin D1 and p16 in patients with intermediate - risk head and neck squamous cell carcinoma treated with docetaxel and concurrent radiotherapy .", "label": "", "metadata": {}, "score": "49.17817"}
{"text": "Irradiated breast cancer cell lines knocked down for CDK4 display increased frequencies of apoptosis .( A ) Cells stably expressing pLKO.1 , shCDK2 or shCDK4 were unirradiated ( basal ) , irradiated at 2 or 4 Gy .", "label": "", "metadata": {}, "score": "49.18276"}
{"text": "13008_2013_181_MOESM3_ESM.pdf Additional file 3 : Silencing of Cdk4 promotes apoptosis .Cells stably expressing pLKO.1 , shCDK2 or shCDK4 were irradiated at 2 Gy .The basal levels were determined in unirradiated cells .", "label": "", "metadata": {}, "score": "49.294235"}
{"text": "Other molecules , including cyclin A and p21 CIP1 , were upregulated in both ER - PR - HER2- and MCF10A cells after irradiation , while cyclin D1 levels did not change .", "label": "", "metadata": {}, "score": "49.335594"}
{"text": "10.1038/onc.2010.238 PubMed View Article .Coco Martin JM , Balkenende A , Verschoor T , Lallemand F , Michalides R : Cyclin D1 overexpression enhances radiation - induced apoptosis and radiosensitivity in a breast tumor cell line .", "label": "", "metadata": {}, "score": "49.352097"}
{"text": "DrugBank Targets : 11 1 .Epidermal growth factor receptor ; 2 .Receptor tyrosine - protein kinase erbB-2 .Lapatinib inhibits ErbB - driven tumor ; cell growth in vitro and in various animal models . ; An additive effect was demonstrated in an in vitro study when lapatinib and 5-FU ( the ; active metabolite of capecitabine ) were used in combination in the 4 tumor cell lines tested .", "label": "", "metadata": {}, "score": "49.587902"}
{"text": "A recent report also demonstrated that enhanced cyclin D1 results in enhanced DNA repair and radioresistance [ 58 ] .This report postulates that cyclin D1 promotes DNA repair by interacting with RAD51 within DNA repair foci ; this interaction is promoted by radiation .", "label": "", "metadata": {}, "score": "49.6419"}
{"text": "As a result , pertuzumab inhibits ligand - initiated intracellular signaling through two major signal pathways , mitogen - activated protein ( MAP ) kinase , and phosphoinositide 3-kinase ( PI3 K ) .", "label": "", "metadata": {}, "score": "49.648354"}
{"text": "Importantly , knockdown of CDK2 did not affect CDK4 levels and vice versa , demonstrating that specific knockdowns were achieved .To assess whether silencing of CDK4 altered radioresistance in other breast cancer subtypes , we generated HCC1954 and SKBR3 cells ( both ER - PR - HER2 + cell lines ) knocked down for CDK4 ( Figure 1 C ) .", "label": "", "metadata": {}, "score": "49.889084"}
{"text": "Downregulated CDK4 sensitizes breast cancer cells to radiation .After cell lines stably silenced for CDK2 and CDK4 were established , all cell lines received ionizing radiation at doses ranging between 0 to 8 Gy .", "label": "", "metadata": {}, "score": "49.910316"}
{"text": "The levels of PP2A and PP2B were further determined by immunoblotting with anti - PP2A and anti - PP2B antibodies .Cells transfected with pLKO.1 were used as control .", "label": "", "metadata": {}, "score": "49.950047"}
{"text": "Increased CDK2 kinase activity drives Herceptin resistance in vitro and in vivo [ 41 , 42 ] .Deregulated CDK4/CDK6 activities have also been associated with decreased survival and resistance to various therapies .", "label": "", "metadata": {}, "score": "50.232555"}
{"text": "10.1038/369669a0 PubMed View Article .Zhou P , Jiang W , Zhang YJ , Kahn SM , Schieren I , Santella RM , Weinstein IB : Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells .", "label": "", "metadata": {}, "score": "50.245464"}
{"text": "PubMed .Niu MY , Menard M , Reed JC , Krajewski S , Pratt MA : Ectopic expression of cyclin D1 amplifies a retinoic acid - induced mitochondrial death pathway in breast cancer cells .", "label": "", "metadata": {}, "score": "50.24762"}
{"text": "In our studies , we tested whether radiosensitization was a consequence of cell cycle inhibition by silenced CDK4 , altered DNA break repair , or through the activation of an apoptotic program .", "label": "", "metadata": {}, "score": "50.2516"}
{"text": "PubMed .Bostrom P , Soderstrom M , Palokangas T , Vahlberg T , Collan Y , Carpen O , Hirsimaki P : Analysis of cyclins A , B1 , D1 and E in breast cancer in relation to tumour grade and other prognostic factors .", "label": "", "metadata": {}, "score": "50.356766"}
{"text": "\u03b2 - actin was used as a loading control .( B ) Cells stably expressing control pLKO.1 were treated with the CDK4/6 inhibitor PD0332991 and irradiated at 0 , 2 and 4 Gy .", "label": "", "metadata": {}, "score": "50.390106"}
{"text": "In the most PHA-848125-sensitive cell line , PHA-848125 induces a concentration - dependent G(1 ) arrest .[ 2 ] PHA-848125 also impairs phosphorylation of the retinoblastoma protein at CDK2 and CDK4 specific sites , reduces retinoblastoma protein and cyclin A levels , and increases p21(Cip1 ) , p27(Kip1 ) and p53 expression .", "label": "", "metadata": {}, "score": "50.399586"}
{"text": "MYL Performed Western blots for cleaved PARP and LC3A/3B in the presence of shCDK4 and the CDK4/CDK6 inhibitor , immunocytochemistry for phospho - histone 3 Contributed and modified figures and was involved in manuscript editing .", "label": "", "metadata": {}, "score": "50.521248"}
{"text": "10.1038/sj.bjc.6602735 PubMed Central PubMed View Article .Strand C , Ahlin C , Bendahl PO , Fjallskog ML , Hedenfalk I , Malmstrom P , Ferno M : Combination of the proliferation marker cyclin A , histological grade , and estrogen receptor status in a new variable with high prognostic impact in breast cancer .", "label": "", "metadata": {}, "score": "50.629093"}
{"text": "The drugs aminoglutethimide and chlorambucil and the compounds biochanin a and diethylstilbestrol have been mentioned in the context of this disorder .Affiliated tissues include breast , skeletal muscle and bone .", "label": "", "metadata": {}, "score": "50.662994"}
{"text": "The presence of increased levels of cleaved caspase-3 and of cleaved PARP in all irradiated cells down regulated for CDK4 indicated that apoptosis was a significant driver of radioresistance in mammary epithelial and breast cancer cells .", "label": "", "metadata": {}, "score": "50.759377"}
{"text": "On the other hand , it elevated cleaved PARP in MDA - MB-231 shCDK4 cells level compared to the negative controls .Knockdown PP2A in MCF10A cells silenced for CDK4 under the same conditions was not successful .", "label": "", "metadata": {}, "score": "50.763397"}
{"text": "In the present study , we addressed whether the G1/S cell cycle regulatory machinery influences radioresistance in MCF10A , ER - PR - HER2- , and ER - PR - HER2 + cells .", "label": "", "metadata": {}, "score": "50.834026"}
{"text": "In contrast to studies showing that increased cyclin D1 activity results in radioresistance through increasing cellular DNA repair capacity , all breast cancer cells tested in this study efficiently repaired DNA breaks irrespective of CDK4 levels , as indicated by the efficient clearance of H2AX foci after radiation .", "label": "", "metadata": {}, "score": "50.86837"}
{"text": "In vitro , Herceptin - mediated ADCC has been shown to be preferentially exerted on HER2 overexpressing cancer cells compared with cancer cells that do not overexpress HER2 . ; .", "label": "", "metadata": {}, "score": "50.95345"}
{"text": "Various mechanisms have been postulated to explain how cyclin D1/CDK4 leads to radioresistance or radiosensitivity of various cells .Inducible expression of cyclin D1 in MCF7 breast cancer cells leads to radiosensitivity through activation of the p53 pathway [ 60 ] .", "label": "", "metadata": {}, "score": "51.084167"}
{"text": "CO;2-T PubMed View Article .Umekita Y , Ohi Y , Sagara Y , Yoshida H : Overexpression of cyclinD1 predicts for poor prognosis in estrogen receptor - negative breast cancer patients .", "label": "", "metadata": {}, "score": "51.134384"}
{"text": "Separate analyses of the unselected and selected patient groups showed a statistically significant effect of the combination on progression , including a median PFS of 26.1 months versus 5.7 months with letrozole alone in the first part of the study .", "label": "", "metadata": {}, "score": "51.210136"}
{"text": "Reis - Filho JS , Savage K , Lambros MB , James M , Steele D , Jones RL , Dowsett M : Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas : an immunohistochemical and chromogenic in situ hybridisation analysis .", "label": "", "metadata": {}, "score": "51.429256"}
{"text": "Estrogen receptor - positive disease and HER2-negative disease .Exclusion Criteria : .Prior treatment with fulvestrant , PI3 K inhibitor , or mTOR inhibitor for advanced breast cancer or MBC .", "label": "", "metadata": {}, "score": "51.567078"}
{"text": "Such drugs would be expected to slow disease progression and improve PFS .My hypothesis is that the next big step in therapy will be the combination of anti - metastatic agents with anti - mitotics , which was not tested here , \" Norton said .", "label": "", "metadata": {}, "score": "51.643852"}
{"text": "Continued approval for this indication ; may be contingent upon verification and description of clinical benefit in ; confirmatory trials .DrugBank Targets : 11 1 .", "label": "", "metadata": {}, "score": "51.645126"}
{"text": "( PDF 19 KB ) .13008_2013_181_MOESM2_ESM.pdf Additional file 2 : Downregulation of Cdk4 does not alter rates of DNA break repair .Non - infected cells and cells stably expressing pLKO.1 , shCDK2 or shCDK4 were irradiated at 2 Gy .", "label": "", "metadata": {}, "score": "51.847855"}
{"text": "This is contrary to our studies revealing that knockdown of CDK4 synergizes with radiation to induce apoptosis in breast cancer cells and MCF10A controls .The only cell in which radiation synergized with inhibition of CDK4/CDK6 was MDA - MB-468 , a cell that is insensitive to growth inhibition by PD0332991 .", "label": "", "metadata": {}, "score": "51.912865"}
{"text": "PubMed .Roy PG , Pratt N , Purdie CA , Baker L , Ashfield A , Quinlan P , Thompson AM : High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer .", "label": "", "metadata": {}, "score": "51.93255"}
{"text": "Tamoxifen inhibits the induction of rat ; mammary carcinoma induced by dimethylbenzanthracene ( DMBA ) and causes the regression of ; already established DMBA - induced tumors .", "label": "", "metadata": {}, "score": "52.03125"}
{"text": "PubMed View Article .Solin LJ : The impact of adding radiation treatment after breast conservation surgery for ductal carcinoma in situ of the breast .", "label": "", "metadata": {}, "score": "52.0962"}
{"text": "( B ) Western blot analyses of lysates prepared from various unirradiated human breast cancer cell lines ( triple negative and ER - PR - HeR2 + and MCF10A ) were immunoblotted with anti - cyclin D1 antibody .", "label": "", "metadata": {}, "score": "52.14602"}
{"text": "10.1093/jnci / djs002 PubMed Central PubMed View Article .Liang Y , Gao H , Lin SY , Goss JA , Brunicardi FC , Li K : siRNA - based targeting of cyclin E overexpression inhibits breast cancer cell growth and suppresses tumor development in breast cancer mouse model .", "label": "", "metadata": {}, "score": "52.211"}
{"text": "While MCF10A cells silenced for CDK4 displayed a significant proportion of caspase-3-positive cells under non - irradiated and with 2 Gy radiation , MDA - MB-468 cells silenced for CDK4 displayed a significant elevation in apoptosis only when irradiated at 2 and 4 Gy .", "label": "", "metadata": {}, "score": "52.22602"}
{"text": "Phase 3 .Features : Non - cytotoxic , and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment ( a chemotherapeutic used to treat many cancers ) .", "label": "", "metadata": {}, "score": "52.294247"}
{"text": "Chen L.Z. .Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines .Konstantinov S.M ....Berger M.R. .Can expression of apoptosis genes , bcl-2 and bax , predict survival and responsiveness to chemotherapy in node - negative breast cancer patients ?", "label": "", "metadata": {}, "score": "52.29963"}
{"text": "Patients with advanced or Metastatic Breast Cancer ( MBC ) who have previously received treatment with an aromatase inhibitor .Patients will receive treatment with GDC-0941 + fulvestrant or GDC-0980 + fulvestrant or placebo + fulvestrant .", "label": "", "metadata": {}, "score": "52.379425"}
{"text": "Cyproterone , norethindrone , medroxyprogesterone and levonorgestrel are less potent local human growth hormone and insulin - like growth factor I secretion stimulators than progesterone in human breast cancer explants expressing the estrogen receptor .", "label": "", "metadata": {}, "score": "52.461914"}
{"text": "Even though the CDK4/CDK6 inhibitor has shown promise in preclinical trials , cells acquire resistance through the upregulation of CDK2 activity [ 98 ] .", "label": "", "metadata": {}, "score": "52.54554"}
{"text": "Conclusion .We conclude that stable knockdown of CDK4 enhances the effects of radiation by enhancing apoptotic pathways .This result has implications for future therapies , as patients can be treated with radiation or chemotherapeutic agents and with doses of CDK4/CDK6 inhibitors that do not block the cell cycle .", "label": "", "metadata": {}, "score": "52.597332"}
{"text": "These in vitro findings suggest non - crossresistance ; between these two agents . ; Hormone receptor - positive breast cancer cells ( with ER [ Estrogen Receptor ] and/or PgR ; [ Progesterone Receptor ] ) that coexpress the HER2 tend to be resistant to established endocrine ; therapies .", "label": "", "metadata": {}, "score": "52.615715"}
{"text": "Indications and Usage : 13 IXEMPRA , a microtubule inhibitor , in combination with capecitabine is ; indicated for the treatment of metastatic or locally advanced breast ; cancer in patients after failure of an anthracycline and a taxane ( 1 ) . ; IXEMPRA as monotherapy is indicated for the treatment of metastatic ; or locally advanced breast cancer in patients after failure of an ; anthracycline , a taxane , and capecitabine ( 1 ) .", "label": "", "metadata": {}, "score": "52.63153"}
{"text": "Low affinity immunoglobulin gamma Fc region receptor III - A .Herceptin has been shown , in both in vitro assays and in animals , to inhibit the proliferation of human tumor cells that overexpress HER2 .", "label": "", "metadata": {}, "score": "52.692776"}
{"text": "The experiments indicate that the double stranded DNA repair capacity of all cells analyzed in this study was intact .Table 5 .Comparison of \u03b3 - H2AX between control ( pLKO.1 ) and treatment ( shCDK4 ) groups .", "label": "", "metadata": {}, "score": "52.721825"}
{"text": "Based on these results , Joyce A. O'Shaughnessy , MD , questions the efficacy of the 1 mg dose of anastrozole as a first - line treatment in this setting .", "label": "", "metadata": {}, "score": "52.74674"}
{"text": "10.1186/1747 - 1028 - 6 - 2 PubMed Central PubMed View Article .Zeng X , Shaikh FY , Harrison MK , Adon AM , Trimboli AJ , Carroll KA , Sharma N , Timmers C , Chodosh LA , Leone G , Saavedra HI : The Ras oncogene signals centrosome amplification in mammary epithelial cells through cyclin D1/Cdk4 and Nek2 .", "label": "", "metadata": {}, "score": "52.803436"}
{"text": "The potency of PHA-848125 toward CDKs and 38 additional kinases belonging to an in - house Kinase Selectivity Screening panel is evaluated , and the relevant IC50s are determined .", "label": "", "metadata": {}, "score": "52.926987"}
{"text": "Prior therapy with commercially available inhibitor of EGFR ( including but not limited to gefitinib , erlotinib , lapatinib or cetuximab ) or experimental inhibitors of EGFR is prohibited .", "label": "", "metadata": {}, "score": "52.95038"}
{"text": "10.1002/stem.620 PubMed View Article .Cerqueira A , Santamaria D , Martinez - Pastor B , Cuadrado M , Fernandez - Capetillo O , Barbacid M : Overall Cdk activity modulates the DNA damage response in mammalian cells .", "label": "", "metadata": {}, "score": "52.966133"}
{"text": "PubMed View Article .Cheung P , Allis CD , Sassone - Corsi P : Signaling to chromatin through histone modifications .Cell 2000 , 103 : 263 - 271 .", "label": "", "metadata": {}, "score": "53.083237"}
{"text": "Additionally , high cyclin E expression predicts a poor prognosis in breast cancer [ 36 , 37 ] .Unregulated CDK2 activity may result in poorer survival due to the modulation of responses to various therapeutic agents .", "label": "", "metadata": {}, "score": "53.18852"}
{"text": "Additional experiments are required to address how CDK4 regulates PP2A levels ; that regulation may result from increased protein stability , increased degradation , or enhanced de - repression of E2F target genes upon CDK4 silencing .", "label": "", "metadata": {}, "score": "53.201508"}
{"text": "Besides being distinguished by their ER , PR , or Her2 status , the various breast cancer subtypes exhibit deregulated expression of proteins that ensure progression through the G1/S phase of the cell cycle .", "label": "", "metadata": {}, "score": "53.427692"}
{"text": "Flavopiridol is initially found to inhibit EGFR and PKA .Phase 1/2 .SNS-032 ( BMS-387032 ) has firstly been described as a selective inhibitor of CDK2 with IC50 of 48 nM in cell - free assays and is 10- and 20-fold selective over CDK1/CDK4 .", "label": "", "metadata": {}, "score": "53.49813"}
{"text": "Table 3 .Comparison of BrdU between control ( pLKO.1 ) and treatment ( shCDK4 ) groups .To measure if knockdown of CDK4 radiosensitizes cells by signaling mitotic blocks , cells were immunostained for phospho - histone 3 after irradiation .", "label": "", "metadata": {}, "score": "53.53329"}
{"text": "13008_2013_181_MOESM1_ESM.pdf Additional file 1 : Radiosensitivity imparted by downregulated Cdk4 is not caused by impaired proliferation .( A ) Cells stably expressing control pLKO.1 , shCDK2 or shCDK4 were unirradiated ( Basal ) or irradiated at 2 Gy .", "label": "", "metadata": {}, "score": "53.608505"}
{"text": "10.1074/jbc .M112.365494PubMed Central PubMed View Article .Roberts PJ , Bisi JE , Strum JC , Combest AJ , Darr DB , Usary JE , Zamboni WC , Wong KK , Perou CM , Sharpless NE : Multiple roles of cyclin - dependent kinase 4/6 inhibitors in cancer therapy .", "label": "", "metadata": {}, "score": "53.643394"}
{"text": "PubMed Central PubMed View Article .Sablina AA , Hahn WC : SV40 small T antigen and PP2A phosphatase in cell transformation .Cancer Metastasis Rev 2008 , 27 : 137 - 146 .", "label": "", "metadata": {}, "score": "53.92771"}
{"text": "A pLKO.1 lentiviral vector containing a randomized shRNA sequence was used as control .After puromycin selection , the surviving cells were pooled .The lysates prepared from the infected cells were immunoblotted with anti - CDK2 or anti - CDK4 antibodies to confirm the knockdown efficiency .", "label": "", "metadata": {}, "score": "53.941624"}
{"text": "Prediction of pathogenic mutations in patients with early - onset breast cancer by family history .Lalloo F ....Evans D.G. .Autocrine growth factor revisited : PC - cell - derived growth factor ( progranulin ) , a critical player in breast cancer tumorigenesis .", "label": "", "metadata": {}, "score": "54.020706"}
{"text": "In vitro studies have shown that olaparib - induced cytotoxicity may involve inhibition of ; PARP enzymatic activity and increased formation of PARP - DNA complex , resulting in disruption of cellular homeostasis ; and cell death .", "label": "", "metadata": {}, "score": "54.11664"}
{"text": "Michalas S. .Prognostic value of cytosolic p53 protein in breast cancer .Montero S .... Colomer R. .Expression of a novel factor , com1 , in early tumor progression of breast cancer .", "label": "", "metadata": {}, "score": "54.152107"}
{"text": "None of the cell lines knocked down for CDK2 displayed radiosensitization .In contrast , all cell lines knocked down for CDK4 were significantly radiosensitized , and a CDK4/CDK6 inhibitor sensitized MDA - MB-468 to radiation induced apoptosis .", "label": "", "metadata": {}, "score": "54.17964"}
{"text": "Mechanism of Action : 13 Target : estrogen receptors Action : competitor with estraidiol FDA : NOLVADEX is a nonsteroidal agent that has demonstrated potent antiestrogenic properties in ; animal test systems .", "label": "", "metadata": {}, "score": "54.291885"}
{"text": "PubMed .Clin Cancer Res 2008 , 14 : 1767 - 1774 .CCR-07 - 4122 PubMed View Article .Hui R , Finney GL , Carroll JS , Lee CS , Musgrove EA , Sutherland RL : Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells .", "label": "", "metadata": {}, "score": "54.319187"}
{"text": "Also , the dephosphorylation of Bcl2 by PP2A promotes its anti - apoptotic activity ; this event may enhance Bcl2 's oncogenic potential [ 109 ] .", "label": "", "metadata": {}, "score": "54.58938"}
{"text": "10.1073/pnas.1014835108 PubMed Central PubMed View Article .Nahta R , Takahashi T , Ueno NT , Hung MC , Esteva FJ : P27(kip1 ) down - regulation is associated with trastuzumab resistance in breast cancer cells .", "label": "", "metadata": {}, "score": "54.65194"}
{"text": "Tubulin beta-3 chain .Ixabepilone ; blocks cells in the mitotic phase of the cell division cycle , leading to cell death .Malady that Drug Treats : HER2-positive metastatic breast cancer .", "label": "", "metadata": {}, "score": "54.822052"}
{"text": "Receptor tyrosine - protein kinase erbB-2 .Mechanism of Action : 13 Target : microtubule Action : inhibitor FDA : Ado - trastuzumab emtansine is a HER2-targeted antibody - drug conjugate .", "label": "", "metadata": {}, "score": "54.89846"}
{"text": "In this trial , anastrozole was administered at 1 mg daily alone or in combination with fulvestrant at 500 mg on day 1 and 250 mg thereafter .", "label": "", "metadata": {}, "score": "54.901047"}
{"text": "M409080200 PubMed View Article .Lee J , Desiderio S : Cyclin A / CDK2 regulates V(D)J recombination by coordinating RAG-2 accumulation and DNA repair .", "label": "", "metadata": {}, "score": "54.933617"}
{"text": "Reduction in Breast Cancer Incidence in High Risk Women : ; NOLVADEX is indicated to reduce the incidence of breast cancer in women at high risk for ; breast cancer .", "label": "", "metadata": {}, "score": "55.005768"}
{"text": "; The safety of PERJETA administered for greater than 6 cycles for ; early breast cancer has not been established .DrugBank Targets : 11 1 .", "label": "", "metadata": {}, "score": "55.084915"}
{"text": "J Clin Invest 2012 , 122 : 833 - 843 .10.1172/JCI60256 PubMed Central PubMed View Article .Garcia A , Cayla X , Guergnon J , Dessauge F , Hospital V , Rebollo MP , Fleischer A , Rebollo A : Serine / threonine protein phosphatases PP1 and PP2A are key players in apoptosis .", "label": "", "metadata": {}, "score": "55.098717"}
{"text": "Phase 3 .It is 7.5-fold more selective for CDK1/2/4/6 than CDK7 .Flavopiridol is initially found to inhibit EGFR and PKA .Phase 1/2 .", "label": "", "metadata": {}, "score": "55.10379"}
{"text": "We did not observe significant dephosphorylation of Bcl2 in any of the cell lines , suggesting that upregulation of PP2A in breast cancer cells exclusively dephosphorylates Bad ser136 without significantly affecting other Bcl family members .", "label": "", "metadata": {}, "score": "55.111755"}
{"text": "PubMed .Gillett C , Fantl V , Smith R , Fisher C , Bartek J , Dickson C , Barnes D , Peters G : Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining .", "label": "", "metadata": {}, "score": "55.12488"}
{"text": "10.1007/s004280050240 PubMed View Article .Kenny FS , Hui R , Musgrove EA , Gee JM , Blamey RW , Nicholson RI , Sutherland RL , Robertson JF : Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor - positive breast cancer .", "label": "", "metadata": {}, "score": "55.148888"}
{"text": "Based on our data we conclude that knockdown of CDK4 activity sensitizes breast cancer cells to radiation by activating apoptosis pathways .Keywords .CDK4 CDK2 Radiation Bad Radioresistance Radiosensitization Breast cancer Apoptosis .", "label": "", "metadata": {}, "score": "55.171024"}
{"text": "[ 4 ] .Protocol ( Only for Reference ) .Inhibition of kinase activity by PHA-848125 is assessed using a strong anion exchanger ( Dowex 1X8 resin)-based assay in robotized format run on 384-well plates .", "label": "", "metadata": {}, "score": "55.3894"}
{"text": "10.1101/gad.8.14.1627 PubMed View Article .Deans AJ , Khanna KK , McNees CJ , Mercurio C , Heierhorst J , McArthur GA : Cyclin - dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers .", "label": "", "metadata": {}, "score": "55.537224"}
{"text": "Likewise , we detected slightly elevated cleaved PARP levels in MDA - MB-468 shCDK4 cells irradiated with 2 Gy relative to MDA - MB-468 pLKO.1 cells .", "label": "", "metadata": {}, "score": "55.54027"}
{"text": "This research project was supported by R01 CA151521 from the National Institutes of Health , the Georgia Cancer Coalition , The Sindab Triple Negative Breast Cancer Foundation , and by the Emory University Integrated Cellular Imaging Microscopy Core of the Winship Cancer Institute comprehensive cancer center grant , P30CA138292 .", "label": "", "metadata": {}, "score": "55.559715"}
{"text": "Materials and methods .Cell culture .A human mammary epithelial cell line ( MCF10A ) and breast cancer cell lines ( ER - PR - HER2-:HCC1806 , HS578 , MDA - MB-231 , MDA - MB-468 ; ER - PR - HER2 + : SKBR3 and HCC1954 ) , were purchased from ATCC ( Rockville , MD ) , or obtained through collaborators .", "label": "", "metadata": {}, "score": "55.602867"}
{"text": "This suggests synergy between downregulation of CDK4 and irradiation in regards to apoptosis .To establish how absence of CDK4 cooperates with radiation to enhance cell death , we screened various Bcl family members .", "label": "", "metadata": {}, "score": "55.72844"}
{"text": "Analyses revealed that most of the breast cancer cell lines tested in this study showed resistance to radiation with a statistically significantly increased IC 50 comparing to the immortalized MCF10A cells ( Table 1 ) .", "label": "", "metadata": {}, "score": "55.735695"}
{"text": "10.1093/jncimonographs / lgq020 PubMed View Article .Kim SI , Park S , Park HS , Kim YB , Suh CO , Park BW : Comparison of Treatment Outcome Between Breast - Conservation Surgery with Radiation and Total Mastectomy without Radiation in Patients with One to Three Positive Axillary Lymph Nodes .", "label": "", "metadata": {}, "score": "55.74234"}
{"text": "Results .Molecular markers common to all cell lines were overexpressed , including cyclin A1 and cyclin D1 , which impinge on CDK2 and CDK4 activities , respectively .", "label": "", "metadata": {}, "score": "55.852783"}
{"text": "Our results indicate lower levels of phospho - Bad at ser136 upon CDK4 silencing and ionizing radiation , which has been shown to signal apoptosis .", "label": "", "metadata": {}, "score": "55.88459"}
{"text": "Another mechanism that can explain the radiosensitization of cells after CDK4 silencing is that its loss potentially enhances frequencies of apoptosis .A pilot experiment established the window of maximal apoptosis following irradiation .", "label": "", "metadata": {}, "score": "55.97458"}
{"text": "Gregoraszczuk E.L. .The menopause , hormone replacement therapy and breast cancer .Marsden J. .Loss of fragile histidine triad expression and metastasis in breast cancer].", "label": "", "metadata": {}, "score": "55.981346"}
{"text": "Even though CDK2 and CDK4 are largely dispensable in the entry and progression through S phase , they are important mediators of mammary tumorigenesis in mice , as ablation of either CDK2 or CDK4 can prevent mouse mammary tumorigenesis triggered by HER2/Neu [ 94 , 95 ] .", "label": "", "metadata": {}, "score": "56.187874"}
{"text": "10.1038/sj.onc.1204453 PubMed View Article .Zhou Q , Fukushima P , DeGraff W , Mitchell JB , Stetler Stevenson M , Ashkenazi A , Steeg PS : Radiation and the Apo2L / TRAIL apoptotic pathway preferentially inhibit the colonization of premalignant human breast cells overexpressing cyclin D1 .", "label": "", "metadata": {}, "score": "56.222965"}
{"text": "The oncogenic capacity of cyclin D1/CDK4/CDK6 in experimental models , including mouse models of mammary carcinogenesis has been established [ 45 - 47 ] .", "label": "", "metadata": {}, "score": "56.26184"}
{"text": "10.1038/nature06046 PubMed View Article .Diril MK , Ratnacaram CK , Padmakumar VC , Du T , Wasser M , Coppola V , Tessarollo L , Kaldis P : Cyclin - dependent kinase 1 ( Cdk1 ) is essential for cell division and suppression of DNA re - replication but not for liver regeneration .", "label": "", "metadata": {}, "score": "56.31801"}
{"text": "10.1073/pnas.96.7.3940 PubMed Central PubMed View Article .Harrison Pitner MK , Saavedra HI : Cdk4 and nek2 signal binucleation and centrosome amplification in a her2 + breast cancer model .", "label": "", "metadata": {}, "score": "56.400486"}
{"text": "10.1002/hed.20632 PubMed View Article .Nature 2011 , 474 : 230 - 234 .10.1038/nature10155 PubMed Central PubMed View Article .Shimura T , Kakuda S , Ochiai Y , Nakagawa H , Kuwahara Y , Takai Y , Kobayashi J , Komatsu K , Fukumoto M : Acquired radioresistance of human tumor cells by DNA - PK / AKT / GSK3beta - mediated cyclin D1 overexpression .", "label": "", "metadata": {}, "score": "56.428055"}
{"text": "\u03b2 - actin was used as a loading control .( C ) Cells stably expressing shCDK4 was transfected with siRNA targeting the PP2A catalytic unit for 48 hours and irradiated at 0 , 2 and 4 Gy .", "label": "", "metadata": {}, "score": "56.43479"}
{"text": "PubMed .Seshadri R , Lee CS , Hui R , McCaul K , Horsfall DJ , Sutherland RL : Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis .", "label": "", "metadata": {}, "score": "56.47113"}
{"text": "CAN-03 - 3900 PubMed View Article .Buckley MF , Sweeney KJ , Hamilton JA , Sini RL , Manning DL , Nicholson RI , deFazio A , Watts CK , Musgrove EA , Sutherland RL : Expression and amplification of cyclin genes in human breast cancer .", "label": "", "metadata": {}, "score": "56.504646"}
{"text": "Protein tyrosine kinase activity in 350 T1/T2 , N0/N1 breast cancer .Preliminary results .Bolla M ....Chambaz E. .GnRH analogs in benign breast disease and breast cancer chemoprevention .", "label": "", "metadata": {}, "score": "56.509254"}
{"text": "Protein lysates were then prepared at different times ( 0 , 0.5 , 1 & 2 hours ) post - irradiation and were immunoblotted with anti - Bad(ser136 ) , anti - Mcl-1(ser159/thr163 ) and anti - Bcl-2(ser70 ) antibodies , and their counterparts detecting total levels of those proteins .", "label": "", "metadata": {}, "score": "56.548542"}
{"text": "Both normal and tumor cells ; metabolize 5-FU to 5-fluoro-2 -deoxyuridine monophosphate ( FdUMP ) and 5-fluorouridine ; triphosphate ( FUTP ) .", "label": "", "metadata": {}, "score": "56.550285"}
{"text": "The \u03b3 - H2AX results obtained by immunocytochemistry were independently investigated in MCF10A , MDA - MB-231 , and MDA - MB-468 cells using flow cytometry .", "label": "", "metadata": {}, "score": "56.55924"}
{"text": "When TMZ plus BG are used in combination with PHA-848125 against cultured normal melanocytes , neither synergistic nor additive antiproliferative effects are observed .[ 2 ] .", "label": "", "metadata": {}, "score": "56.578697"}
{"text": "A cocktail of siRNAs targeting the PP2A catalytic unit was transiently transfected into cells stably expressing shCDK4 and cells were irradiated at 0 , 2 and 4 Gy after 48 hours transfection .", "label": "", "metadata": {}, "score": "56.601936"}
{"text": "Treatment of K - Ras(G12D)LA2 mice with PHA-848125 ( 40 mg / kg twice daily for 10 days ) results in significant tumor growth inhibition at the end of the treatment and is accompanied by a reduction in the cell membrane turnover .", "label": "", "metadata": {}, "score": "56.605045"}
{"text": "10.1371/journal.pone.0065971 PubMed Central PubMed View Article .Saavedra HI , Maiti B , Timmers C , Altura R , Tokuyama Y , Fukasawa K , Leone G : Inactivation of E2F3 results in centrosome amplification .", "label": "", "metadata": {}, "score": "56.632736"}
{"text": "The discovery of molecular markers associated with various breast cancer subtypes has greatly improved the treatment and outcome of breast cancer patients .Unfortunately , breast cancer cells acquire resistance to various therapies .", "label": "", "metadata": {}, "score": "56.659027"}
{"text": "10.1016/j.ccr.2007.10.017 PubMed Central PubMed View Article .Bukholm IK , Berner JM , Nesland JM , Borresen - Dale AL : Expression of cyclin Ds in relation to p53 status in human breast carcinomas .", "label": "", "metadata": {}, "score": "56.67592"}
{"text": "10.1186/2041 - 9414 - 2 - 3 PubMed Central PubMed View Article .Adon AM , Zeng X , Harrison MK , Sannem S , Kiyokawa H , Kaldis P , Saavedra HI : Cdk2 and Cdk4 regulate the centrosome cycle and are critical mediators of centrosome amplification in p53-null cells .", "label": "", "metadata": {}, "score": "56.85804"}
{"text": "Clin Cancer Res 2009 , 15 : 441 - 451 .CCR-08 - 1791 PubMed View Article .Gauthier ML , Berman HK , Miller C , Kozakeiwicz K , Chew K , Moore D , Rabban J , Chen YY , Kerlikowske K , Tlsty TD : Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal - like breast tumors .", "label": "", "metadata": {}, "score": "56.880688"}
{"text": "Brentani M.M. .HER2 regulatory control of angiopoietin-2 in breast cancer .Carter W.B .... Ward M.D. .Prospective studies of p53 and c - erbB-2 expression in relation to clinicopathological parameters of human ductal breast cancer in the second stage of clinical advancement .", "label": "", "metadata": {}, "score": "56.893906"}
{"text": "The most common adverse events in the P+L arm were neutropenia , leukopenia , fatigue , and anemia .Conclusions : P+L demonstrated a statistically significant improvement in PFS and showed significant clinical benefit as first - line treatment of ER+/HER2- advanced BC .", "label": "", "metadata": {}, "score": "57.000126"}
{"text": "This metabolic error ; can interfere with RNA processing and protein synthesis .DrugBank Targets : 11 1 .Lutropin - choriogonadotropic hormone receptor ; 2 .", "label": "", "metadata": {}, "score": "57.09051"}
{"text": "Moreover , several questions remain unanswered regarding the optimal first - line treatment for these patients .Adding to the quandary , Sara Hurvitz , MD , points out that patients who received prior tamoxifen did not benefit as substantially from the combination .", "label": "", "metadata": {}, "score": "57.110546"}
{"text": "Malady that Drug Treats : metastatic breast cancer .Indications and Usage : 13 HALAVEN is a microtubule inhibitor indicated for the treatment of ; patients with metastatic breast cancer who have previously received ; at least two chemotherapeutic regimens for the treatment of ; metastatic disease .", "label": "", "metadata": {}, "score": "57.14908"}
{"text": "Masinghe SP , Faluyi OO , Kerr GR , Kunkler IH : Breast radiotherapy for occult breast cancer with axillary nodal metastases - does it reduce the local recurrence rate and increase overall survival ?", "label": "", "metadata": {}, "score": "57.21522"}
{"text": "Branda R.F ....Albertini R.J. .Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer .Manni A ....Bartholomew M. .", "label": "", "metadata": {}, "score": "57.228943"}
{"text": "Indications and Usage : 13 ABRAXANE is a microtubule inhibitor indicated for the treatment of : ; Metastatic breast cancer , after failure of combination chemotherapy ; for metastatic disease or relapse within 6 months of adjuvant ; chemotherapy .", "label": "", "metadata": {}, "score": "57.29693"}
{"text": "Please refer to this study by its ClinicalTrials.gov identifier : NCT01437566 .Breast Neoplasms Breast Diseases Neoplasms Neoplasms by Site Skin Diseases Aromatase Inhibitors Fulvestrant Antineoplastic Agents Antineoplastic Agents , Hormonal .", "label": "", "metadata": {}, "score": "57.373295"}
{"text": "Malady that Drug Treats : post menopausal breast cancer .Patients with ER - negative disease and patients ; who did not respond to previous tamoxifen therapy rarely ; responded to ARIMIDEX ( 1.3 ) .", "label": "", "metadata": {}, "score": "57.537064"}
{"text": "PubMed .Jiang W , Kahn SM , Zhou P , Zhang YJ , Cacace AM , Infante AS , Doi S , Santella RM , Weinstein IB : Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control , cell cycle progression and gene expression .", "label": "", "metadata": {}, "score": "57.579178"}
{"text": "Please refer to this study by its ClinicalTrials.gov identifier : NCT01610284 .Breast Neoplasms Breast Diseases Neoplasms Neoplasms by Site Skin Diseases Aromatase Inhibitors Estradiol Fulvestrant Antineoplastic Agents Antineoplastic Agents , Hormonal Enzyme Inhibitors .", "label": "", "metadata": {}, "score": "57.59585"}
{"text": "10.1016/j.breast.2004.08.004 PubMed View Article .Pearce AG , Segura TM , Rintala AC , Rintala - Maki ND , Lee H : The generation and characterization of a radiation - resistant model system to study radioresistance in human breast cancer cells .", "label": "", "metadata": {}, "score": "57.782738"}
{"text": "10.1083/jcb.200903033 PubMed Central PubMed View Article .Ray D , Terao Y , Christov K , Kaldis P , Kiyokawa H : Cdk2-null mice are resistant to ErbB-2-induced mammary tumorigenesis .", "label": "", "metadata": {}, "score": "57.889175"}
{"text": "10.1038/onc.2010.154 PubMed View Article .Dean JL , McClendon AK , Knudsen ES : Modification of the DNA damage response by therapeutic CDK4/6 inhibition .", "label": "", "metadata": {}, "score": "57.907246"}
{"text": "Zaky SS , Lund M , May KA , Godette KD , Beitler JJ , Holmes LR , O'Regan RM , Yu ES , Yu DS , Landry JC : The Negative Effect of Triple - Negative Breast Cancer on Outcome after Breast - Conserving Therapy .", "label": "", "metadata": {}, "score": "57.947655"}
{"text": "Boothman DA , Meyers M , Odegaard E , Wang M : Altered G1 checkpoint control determines adaptive survival responses to ionizing radiation .Mutat Res 1996 , 358 : 143 - 153 .", "label": "", "metadata": {}, "score": "58.007015"}
{"text": "For example , ER+ luminal cells that overexpress cyclin D1 and Rb and display downregulated p16 respond well to cell cycle inhibition by the CDK4/CDK6 specific inhibitor PD-0332991 , while non - luminal / basal cells are refractive to growth inhibition [ 64 ] .", "label": "", "metadata": {}, "score": "58.02507"}
{"text": "Simizu S , Tamura Y , Osada H : Dephosphorylation of Bcl-2 by protein phosphatase 2A results in apoptosis resistance .Cancer Sci 2004 , 95 : 266 - 270 .", "label": "", "metadata": {}, "score": "58.04692"}
{"text": "PubMed .Voduc D , Nielsen TO , Cheang MC , Foulkes WD : The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype .", "label": "", "metadata": {}, "score": "58.08259"}
{"text": "Malady that Drug Treats : Hormone receptor positive metastatic breast cancer .Indications and Usage : 13 FASLODEX is an estrogen receptor antagonist indicated for the : ; Treatment of hormone receptor positive metastatic breast cancer in ; postmenopausal women with disease progression following ; antiestrogen therapy .", "label": "", "metadata": {}, "score": "58.1246"}
{"text": "\u03b2 - actin was used as a loading control .Levels were normalized based on \u03b2 - actin , and are indicated as fold - induction relative to non - irradiated pLKO.1 controls .", "label": "", "metadata": {}, "score": "58.14924"}
{"text": "Mechanism of Action : 13 Target : pituitary gonadotropin ; secretion Action : inhibitor FDA : ZOLADEX is a synthetic decapeptide analogue of GnRH .ZOLADEX acts as an inhibitor of pituitary gonadotropin ; secretion when administered in the biodegradable formulation .", "label": "", "metadata": {}, "score": "58.18827"}
{"text": "DrugBank Targets : 11 1 .Cytochrome P450 19A1 .Mechanism of Action : 13 Target : aromatase enzyme system Action : inhibitor FDA : The growth of some cancers of the breast is stimulated or maintained by estrogens .", "label": "", "metadata": {}, "score": "58.280197"}
{"text": "( B )The number of cells positively stained with cleaved caspase-3 were counted in a population of at least 287 cells and the results are shown as the proportion of positive cells between treatment and control groups .", "label": "", "metadata": {}, "score": "58.46891"}
{"text": "An initial assessment of data from both parts combined showed that overall survival , one of the secondary endpoints of the study , was 37.5 months for those treated with the palbociclib - letrozole combination , and 33.3 months for those treated with letrozole alone .", "label": "", "metadata": {}, "score": "58.52981"}
{"text": "Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell - free assays .It shows no activity against CDK1/2/5 , EGFR , FGFR , PDGFR , InsR , etc .", "label": "", "metadata": {}, "score": "58.61043"}
{"text": "13008_2013_181_MOESM4_ESM.pdf Additional file 4 : CDK4 silencing did not change degree of autophagy .( A ) Cells stably expressing control pLKO.1 and shCDK4 were irradiated at 0 , 2 and 4 Gy .", "label": "", "metadata": {}, "score": "58.72838"}
{"text": "Cells were fixed at different times ( 0 , 6 , 12 , 24 , & 48 hours ) post - irradiation and were subjected to immunostaining with anti - H2A.X antibody ( \u03b3 - H2AX ) and an Alexa Fluor 555 secondary antibody ; DNA was counter - stained with DAPI ( A ) .", "label": "", "metadata": {}, "score": "58.755814"}
{"text": "Malady that Drug Treats : Breast cancer / gastric cancer .Indications and Usage : 13 Herceptin is a HER2/neu receptor antagonist indicated for : ; the treatment of HER2 overexpressing breast cancer ( 1.1 , 1.2 ) .", "label": "", "metadata": {}, "score": "59.00836"}
{"text": "PubMed .Han EK , Begemann M , Sgambato A , Soh JW , Doki Y , Xing WQ , Liu W , Weinstein IB : Increased expression of cyclin D1 in a murine mammary epithelial cell line induces p27kip1 , inhibits growth , and enhances apoptosis .", "label": "", "metadata": {}, "score": "59.035507"}
{"text": "BG is added to the plates 2 hours before TMZ and left in culture for the entire period of cell exposure to the drug .ContS1017rol groups are represented by untreated cells and cells treated with BG or DMSO alone .", "label": "", "metadata": {}, "score": "59.06879"}
{"text": "Treatment with a GnRH agonist for ovarian suppression for at least 3 consecutive months prior to study registration , and remaining on such therapy throughout the course of protocol treatment .", "label": "", "metadata": {}, "score": "59.07853"}
{"text": "( C ) Cells stably expressing pLKO.1 , or shCDK4 were unirradiated ( 0 ) , irradiated at 2 or 4 Gy .Protein lysates were prepared 48 hours later and were subjected to Western blot with anti - cleaved PARP antibody .", "label": "", "metadata": {}, "score": "59.122673"}
{"text": "These experiments suggested that downregulation of CDK4 lead to increases in PP2A , which dephosphorylates phospho - Bad in ser136 .Downregulation of Cdk4 results in impaired phosphorylation of BAD ( ser136 ) and upregulation of protein phosphatase type 2A ( PP2A ) .", "label": "", "metadata": {}, "score": "59.248154"}
{"text": "3831 .10.1073/pnas.1115201109 PubMed Central PubMed View Article .Pagano M , Theodoras AM , Tam SW , Draetta GF : Cyclin D1-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts .", "label": "", "metadata": {}, "score": "59.265522"}
{"text": "Interventions : .Placebo Comparator : Arm II ( placebo ) .Patients receive placebo PO QD on days 1 - 28 and fulvestrant IM on days 1 ( 500 mg ) and 15 ( 250 mg ) of course 1 and on day 1 ( 250 mg ) of each subsequent course .", "label": "", "metadata": {}, "score": "59.30704"}
{"text": "A patient who received an aromatase inhibitor in the adjuvant setting is eligible , regardless of whether they did or did not receive tamoxifen at some point ; .", "label": "", "metadata": {}, "score": "59.361855"}
{"text": "10.1016/j.humpath.2008.03.004 PubMed View Article .Clin Cancer Res 2009 , 15 : 5888 - 5894 .CCR-09 - 0728 PubMed View Article .Span PN , D e - Mulder PH , Sweep FC : Re : p27(Kip1 ) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy .", "label": "", "metadata": {}, "score": "59.525055"}
{"text": "Adding to the quandary , Sara Hurvitz , MD , points out that patients who received prior tamoxifen did not benefit as substantially from the combination .", "label": "", "metadata": {}, "score": "59.708965"}
{"text": "CAN-05 - 2639 PubMed View Article .Harrison MK , Adon AM , Saavedra HI : The G1 phase Cdks regulate the centrosome cycle and mediate oncogene - dependent centrosome amplification .", "label": "", "metadata": {}, "score": "59.780525"}
{"text": "Twenty - five percent of the participants received drug for 5 years .The ; longer - term effects are not known .In this study , there was no impact of tamoxifen on overall or ; breast cancer - related mortality ( see BOXED WARNING at the beginning of the label ) . ; NOLVADEX is indicated only for high - risk women .", "label": "", "metadata": {}, "score": "59.78444"}
{"text": "Wang SL , Li YX , Song YW , Wang WH , Jin J , Liu YP , Liu XF , Yu ZH : Triple - Negative or HER2-Positive Status Predicts Higher Rates of Locoregional Recurrence in Node - Positive Breast Cancer Patients After Mastectomy .", "label": "", "metadata": {}, "score": "59.98481"}
{"text": "( 1.4 ) AFINITOR and AFINITOR DISPERZ are kinase inhibitors indicated for the treatment of : pediatric and adult patients with tuberous sclerosis complex ( TSC ) who have subependymal giant cell astrocytoma ( SEGA ) that requires therapeutic intervention but can not be curatively resected .", "label": "", "metadata": {}, "score": "60.032486"}
{"text": "Objective Tumor Response Rate for Participants With HER2-positive Tumors [ Time Frame : Up to 5 years ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "60.23352"}
{"text": "Cells collected from different time points ( 0 , 6 , 12 , 24 , & 48 hours ) post - irradiation were subjected to immunostaining with anti - Ki67 antibody , an Alexa Fluor secondary and the DNA was counter - stained with DAPI .", "label": "", "metadata": {}, "score": "60.258938"}
{"text": "DrugBank Targets : 11 1 .Tubulin beta-1 chain ; 2 .Apoptosis regulator Bcl-2 ; 3 .Microtubule - associated protein 2 ; 4 .", "label": "", "metadata": {}, "score": "60.297813"}
{"text": "Cells were subjected to immunostaining with anti - cleaved caspase-3 antibody ( arrows ) , and an Alexa Fluor 488 secondary antibody ; DNA was counter - stained with DAPI .", "label": "", "metadata": {}, "score": "60.29996"}
{"text": "Leukemia 2010 , 24 : 679 - 686 .10.1038/leu.2010.6 PubMed View Article .Rogakou EP , Boon C , Redon C , Bonner WM : Megabase chromatin domains involved in DNA double - strand breaks in vivo .", "label": "", "metadata": {}, "score": "60.30351"}
{"text": "Western blot analyses showed that p27 KIP1 levels were higher in untreated ER - PR - HER2- breast cancer cells relative to MCF10A cells and showed no change upon irradiation ( Figure 1 A ) .", "label": "", "metadata": {}, "score": "60.3124"}
{"text": "Microtubule - associated protein tau ; 6 .Nuclear receptor subfamily 1 group I member 2 .Mechanism of Action : 13 Target : free tubulin Action : promoter of assembly FDA : Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is ; essential for mitotic and interphase cellular functions .", "label": "", "metadata": {}, "score": "60.367737"}
{"text": "10.1074/jbc.274.36.25543 PubMed View Article .Preuss U , Landsberg G , Scheidtmann KH : Novel mitosis - specific phosphorylation of histone H3 at Thr11 mediated by Dlk / ZIP kinase .", "label": "", "metadata": {}, "score": "60.48155"}
{"text": "Indications and Usage : 13 ELLENCE Injection is an anthracycline topoisomerase II inhibitor indicated ; as a component of adjuvant therapy in patients with evidence of axillary node ; tumor involvement following resection of primary breast cancer ( 1 ) .", "label": "", "metadata": {}, "score": "60.553043"}
{"text": "Was involved in finalizing the writing of the manuscript .XZ : Performed western blots and caspase , BrdU , Ki67 and \u03b3 - H2AX preliminary and supplementary experiments in the manuscript .", "label": "", "metadata": {}, "score": "60.616394"}
{"text": "We speculate that the differences between cyclin D1 and CDK4/CDK6 inhibition in relation to DNA repair is because cyclin D1 displays functions that are independent of CDK4 .", "label": "", "metadata": {}, "score": "60.640587"}
{"text": "Increased frequencies of \u03b3 - H2AX foci have been extensively used to measure DNA damage by physical agents , oncogenes , or inactive tumor suppressors [ 59 , 73 , 74 ] .", "label": "", "metadata": {}, "score": "60.68277"}
{"text": "This ; indication is approved under accelerated approval based on progression - free ; survival ( PFS ) .Continued approval for this indication may be contingent ; upon verification and description of clinical benefit in a confirmatory trial .", "label": "", "metadata": {}, "score": "60.70739"}
{"text": "Further studies must be performed in order to establish why MCF10A cells silenced for CDK4 display phosphorylated Bad Ser 136 , and still apoptose .Bad ser136 phosphorylation is reversed by various phosphatases , including PP2A and PP1\u03b1 [ 81 , 82 ] .", "label": "", "metadata": {}, "score": "60.713436"}
{"text": "Objective Tumor Response Rate for Participants With HER2-negative Tumors [ Time Frame : Up to 5 years ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "60.788773"}
{"text": "While cyclin D1/CDK4 specifically mediates centrosome amplification triggered by H - Ras G12D , H - Ras G12D & c - Myc [ 97 ] , and in HER2 + breast cancer cells [ 76 ] , silencing of cyclin E or CDK2 have no impact on centrosome amplification in the HER2/Ras systems .", "label": "", "metadata": {}, "score": "60.855347"}
{"text": "All cell lines showed consistently stable decreases in the protein level of CDK2 or CDK4 ( Figure 1 C ) .MCF10A and HCC1806 cells displayed complete downregulation of CDK4 , while MDA - MB-468 and MDA - MB-231 cells showed a partial , but almost complete knockdown of CDK4 .", "label": "", "metadata": {}, "score": "60.855957"}
{"text": "Hormone therapy using fulvestrant may fight breast cancer by lowering the amount of estrogen the body makes .Lapatinib may stop the growth of breast cancer cells by blocking some of the enzymes needed for cell growth .", "label": "", "metadata": {}, "score": "60.923164"}
{"text": "10.1667/0033 - 7587(2001)156[0739:TGACOA]2.0 .CO;2 PubMed View Article .Malumbres M , Barbacid M : Cell cycle , CDKs and cancer : a changing paradigm .", "label": "", "metadata": {}, "score": "60.99717"}
{"text": "Patients with ER - positive locally advanced breast cancer or Metastatic Breast Cancer ( MBC ) .Postmenopausal women with locally advanced breast cancer or Metastatic Breast Cancer whose disease has progressed during or after treatment with an aromatase inhibitor .", "label": "", "metadata": {}, "score": "61.16954"}
{"text": "Wang Q , Gao F , Wang T , Flagg T , Deng X : A nonhomologous end - joining pathway is required for protein phosphatase 2A promotion of DNA double - strand break repair .", "label": "", "metadata": {}, "score": "61.273315"}
{"text": "Epirubicin is also involved in ; oxidation / reduction reactions by generating cytotoxic free radicals .The antiproliferative and cytotoxic activity of epirubicin is thought to result ; from these or other possible mechanisms . ; Epirubicin is cytotoxic in vitro to a variety of established murine and human cell lines and primary cultures of human tumors .", "label": "", "metadata": {}, "score": "61.33689"}
{"text": "Microtubule - associated protein 2 ; 6 .Microtubule - associated protein tau .Mechanism of Action : 13 Target : microtubule Action : inhibitor FDA : ABRAXANE is a microtubule inhibitor that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules ; by preventing depolymerization .", "label": "", "metadata": {}, "score": "61.41574"}
{"text": "10.1016/S0092 - 8674(00)81382 - 3 PubMed View Article .Ayllon V , Cayla X , Garcia A , Roncal F , Fernandez R , Albar JP , Martinez C , Rebollo A : Bcl-2 targets protein phosphatase 1 alpha to Bad .", "label": "", "metadata": {}, "score": "61.462967"}
{"text": "PubMed .Ahmed KM , Fan M , Nantajit D , Cao N , Li JJ : Cyclin D1 in low - dose radiation - induced adaptive resistance .", "label": "", "metadata": {}, "score": "61.49462"}
{"text": "Features : The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers .Dinaciclib ( SCH727965 ) is a novel and potent CDK inhibitor for CDK2 , CDK5 , CDK1 and CDK9 with IC50 of 1 nM , 1 nM , 3 nM and 4 nM in cell - free assays , respectively .", "label": "", "metadata": {}, "score": "61.61358"}
{"text": "Malady that Drug Treats : osteoporosis and reduction of breast cancer risk in postmenopausal women .Indications and Usage : 13 EVISTA is an estrogen agonist / antagonist indicated for ; Treatment and prevention of osteoporosis in postmenopausal women . ; ( 1.1 ) .", "label": "", "metadata": {}, "score": "61.67009"}
{"text": "10.1016/S1535 - 6108(03)00083 - 7 PubMed Central PubMed View Article .Yang E , Zha J , Jockel J , Boise LH , Thompson CB , Korsmeyer SJ : Bad , a heterodimeric partner for Bcl - XL and Bcl-2 , displaces Bax and promotes cell death .", "label": "", "metadata": {}, "score": "61.68507"}
{"text": "10.1093/jnci / djh297 PubMed View Article .Correa C , McGale P , Taylor C , Wang Y , Clarke M , Davies C , Peto R , Bijker N , Solin L , Darby S : Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast .", "label": "", "metadata": {}, "score": "61.742172"}
{"text": "Westermarck J , Hahn WC : Multiple pathways regulated by the tumor suppressor PP2A in transformation .Trends Mol Med 2008 , 14 : 152 - 160 .", "label": "", "metadata": {}, "score": "61.838596"}
{"text": "To establish whether radiosensitization also occurred through autophagy , we probed Western blots with an antibody against LC3A/3B.In MCF10A cells , only the lower band , which is the indicator of autophagy , was detected with no great difference among samples .", "label": "", "metadata": {}, "score": "61.886578"}
{"text": "Letrozole selectively inhibits gonadal steroidogenesis but has no significant effect ; on adrenal mineralocorticoid or glucocorticoid synthesis . ; Letrozole inhibits the aromatase enzyme by competitively binding to the heme of the cytochrome P450 ; subunit of the enzyme , resulting in a reduction of estrogen biosynthesis in all tissues .", "label": "", "metadata": {}, "score": "61.956066"}
{"text": "First , ; FdUMP and the folate cofactor , N5 - 10-methylenetetrahydrofolate , bind to thymidylate synthase ; ( TS ) to form a covalently bound ternary complex .", "label": "", "metadata": {}, "score": "62.085228"}
{"text": "10.1016/0092 - 8674(95)90411 - 5 PubMed View Article .Zha J , Harada H , Yang E , Jockel J , Korsmeyer SJ : Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14 - 3 - 3 not BCL - X(L ) .", "label": "", "metadata": {}, "score": "62.15744"}
{"text": "; Letrozole is a nonsteroidal competitive inhibitor of the aromatase enzyme system ; it inhibits the ; conversion of androgens to estrogens .In adult nontumor- and tumor - bearing female animals , letrozole is ; as effective as ovariectomy in reducing uterine weight , elevating serum LH , and causing the regression of ; estrogen - dependent tumors .", "label": "", "metadata": {}, "score": "62.169754"}
{"text": "; positive early breast cancer who have received two to three years of Incidence of cardiac failure : AROMASIN 0.4 % , tamoxifen 0.3 % ( 6 , ; tamoxifen and are switched to AROMASIN for completion of a total of 6.1 ) .", "label": "", "metadata": {}, "score": "62.18145"}
{"text": "The controversy regarding the role played by the G1/S phase regulatory machinery in radioresistance may be due to the use of normal or transformed cells lines , their tissue of origin , or to the dose and duration of radiation treatments [ 55 , 58 - 60 ] .", "label": "", "metadata": {}, "score": "62.207073"}
{"text": "The small molecule cytotoxin , DM1 , is a microtubule ; inhibitor .Upon binding to sub - domain IV of the HER2 receptor , ado - trastuzumab emtansine ; undergoes receptor - mediated internalization and subsequent lysosomal degradation , resulting in ; intracellular release of DM1-containing cytotoxic catabolites .", "label": "", "metadata": {}, "score": "62.29361"}
{"text": "DrugBank Targets : 11 1 .Estrogen receptor ; 2 .Estrogen receptor beta ; 3 . 3-beta - hydroxysteroid - Delta(8),Delta(7)-isomerase ; 4 .", "label": "", "metadata": {}, "score": "62.308083"}
{"text": "10.1038/onc.2009.170 PubMed View Article .Chen HZ , Tsai SY , Leone G : Emerging roles of E2Fs in cancer : an exit from cell cycle control .", "label": "", "metadata": {}, "score": "62.322823"}
{"text": "Adverse events included neutropenia , leukopenia , fatigue , and anemia .\" It is important that we not only improve the efficacy of the compound , but also that we do not add an undue burden in toxicity , and we are happy that the drug was well tolerated overall , \" said Finn .", "label": "", "metadata": {}, "score": "62.385952"}
{"text": "Radiotherapy is one of the cornerstones in the treatment of patients with breast cancer [ 7 , 8 ] .Radiation greatly reduces the risk of recurrence in women with ductal carcinoma in situ [ 9 , 10 ] and in breast cancer patients who are lymph node positive [ 11 - 13 ] .", "label": "", "metadata": {}, "score": "62.409912"}
{"text": "Women with defects in the BRCA1 and BRCA2 genes have up to an 80 % chance of getting breast cancer .Research has also found that defects in the ErbB-2 gene lead to increased levels of the protein cyclin D1 .", "label": "", "metadata": {}, "score": "62.418343"}
{"text": "PubMed View Article .Chiang CW , Kanies C , Kim KW , Fang WB , Parkhurst C , Xie M , Henry T , Yang E : Protein phosphatase 2A dephosphorylation of phosphoserine 112 plays the gatekeeper role for BAD - mediated apoptosis .", "label": "", "metadata": {}, "score": "62.425777"}
{"text": "DrugBank Targets : 11 1 .Apoptosis regulator Bcl-2 ; 2 .Tubulin beta-1 chain ; 3 .Nuclear receptor subfamily 1 group I member 2 ; 4 .", "label": "", "metadata": {}, "score": "62.475677"}
{"text": "A patient with de novo metastatic breast cancer who had never received endocrine therapy is not eligible ; .A patient who received adjuvant tamoxifen and subsequent therapy with an aromatase inhibitor ( adjuvant or metastatic ) is eligible ; .", "label": "", "metadata": {}, "score": "62.482246"}
{"text": "To establish whether increased DNA repair is responsible for radiation resistance , we measured DNA breaks by detecting \u03b3 - H2AX foci .H2A.X is a variant histone which is phosphorylated on Ser139 ( \u03b3 - H2AX ) by ATM , ATR , or DNA PK at sites of DNA damage to recruit DNA repair enzymes , thus representing an important mark of DNA breaks [ 69 - 71 ] .", "label": "", "metadata": {}, "score": "62.556458"}
{"text": "Lentiviral shRNA transduction .The shRNA constructs against CDK2 or CDK4 were cloned into the lentiviral vector pLKO.1 , which are commercially available from OPEN Biosystems .", "label": "", "metadata": {}, "score": "62.714745"}
{"text": "Likewise , flow cytometry did not reveal any major changes in the percentage of cells in G1 , S , or G2/M phases of the cell cycle in irradiated or non - irradiated cells when comparing shCDK4 cells relative to pLKO.1 controls ( Figure 3 ) .", "label": "", "metadata": {}, "score": "62.722557"}
{"text": "DrugBank Targets : 11 1 .Apoptosis regulator Bcl-2 ; 2 .Tubulin beta-1 chain ; ; 3 .Nuclear receptor subfamily 1 group I member 2 ; 4 .", "label": "", "metadata": {}, "score": "62.726097"}
{"text": "References .Jemal A , Siegel R , Ward E , Hao Y , Xu J , Murray T , Thun MJ : Cancer statistics , 2008 .", "label": "", "metadata": {}, "score": "62.95109"}
{"text": "( 1.1 ) ; Locally advanced or metastatic non - small cell lung cancer ( NSCLC ) , ; as first - line treatment in combination with carboplatin , in patients who ; are not candidates for curative surgery or radiation therapy .", "label": "", "metadata": {}, "score": "62.961815"}
{"text": "10.1093/jnci / djk064 PubMed View Article .Jameel JK , Rao VS , Cawkwell L , Drew PJ : Radioresistance in carcinoma of the breast .", "label": "", "metadata": {}, "score": "62.97272"}
{"text": "This phase II clinical study was funded by Pfizer .Finn declares no conflicts of interest .Slamon has shares of common stocks in Pfizer .", "label": "", "metadata": {}, "score": "63.002884"}
{"text": "PubMed View Article .Satyanarayana A , Kaldis P : Mammalian cell - cycle regulation : several Cdks , numerous cyclins and diverse compensatory mechanisms .", "label": "", "metadata": {}, "score": "63.109688"}
{"text": "Farnesyl pyrophosphate synthase ; 2 .Hydroxylapatite .Mechanism of Action : 13 Target : bone resorption ; FPP synthase Action : inhibitor FDA : The principal pharmacologic action of Aredia is inhibition of bone resorption .", "label": "", "metadata": {}, "score": "63.133545"}
{"text": "HCC1806 , HCC1954 , and SKBR3 cells were cultured in RPMI supplemented with 10 % fetal bovine serum ( FBS ) .HS578 , MDA - MB-231 and MDA - MB-468 cells were cultured in DMEM supplemented with 10 % FBS .", "label": "", "metadata": {}, "score": "63.173836"}
{"text": "Cytoplasmic cyclin D1 then interacts with Bax , suppressing the ability of Bax to induce apoptosis .In another example , long term fractionated irradiation of the human cancer cell lines HepG2 and HeLa induced radioresistance [ 59 ] .", "label": "", "metadata": {}, "score": "63.175575"}
{"text": "Malady that Drug Treats : breast cancer/ metastatic colorectal cancer .DrugBank Targets : 11 1 .Thymidylate synthase ; 2 .DNA ; 3 .", "label": "", "metadata": {}, "score": "63.36945"}
{"text": "Phase 1 .Dinaciclib ( SCH727965 ) is a novel and potent CDK inhibitor for CDK2 , CDK5 , CDK1 and CDK9 with IC50 of 1 nM , 1 nM , 3 nM and 4 nM in cell - free assays , respectively .", "label": "", "metadata": {}, "score": "63.38883"}
{"text": "Radiosensitivity imparted by downregulated CDK4 is not caused by altering cell cycle progression .Cells stably expressing pLKO.1 or shCDK4 were unirradiated ( basal ) , or irradiated at 2 Gy .", "label": "", "metadata": {}, "score": "63.414764"}
{"text": "Chromodomain - helicase - DNA - binding protein 1 ; 2 .DNA topoisomerase 2-alpha ; 3 .DNA .Mechanism of Action : 13 Target : nucleic acid ( DNA and RNA ) and protein synthesis Action : inhibitor FDA : Epirubicin is an anthracycline cytotoxic agent .", "label": "", "metadata": {}, "score": "63.419994"}
{"text": "After overnight incubation , the absorbance is read at 595 nm using a 3550-UV microplate reader .Cell sensitivity to drug treatment is expressed in terms of IC50 ( drug concentration producing 50 % inhibition of cell growth , calculated on the regression line in which absorbance values at 595 nm are plotted against the logarithm of drug concentration ) .", "label": "", "metadata": {}, "score": "63.46483"}
{"text": "Patients will be assessed up to approx . 8.3 months .BKM120 100 mg given daily and fulvestrant 500 mg given intramuscularly at cycle 1 day 1 , cycle 1 day 15 and at day 1 at each cycle thereafter .", "label": "", "metadata": {}, "score": "63.721775"}
{"text": "However , injured hepatocytes do not require CDK1 to proliferate [ 86 ] .Another important function of the CDKs is in DNA repair .Specifically , cyclin D1 , CDK4 [ 58 , 59 , 87 ] , cyclin A1 , and CDK2 have been implicated in DNA repair [ 88 - 92 ] .", "label": "", "metadata": {}, "score": "63.870106"}
{"text": "In postmenopausal women , the absence of changes ; in plasma concentrations of FSH and LH in response to ; fulvestrant treatment ( 250 mg monthly ) suggests no peripheral ; steroidal effects .", "label": "", "metadata": {}, "score": "63.92657"}
{"text": "Microtubule - associated protein 2 ; 6 .Microtubule - associated protein tau .Mechanism of Action : 13 Target : microtubules Action : promoter of assembly & preventor of depolymerization FDA : Paclitaxel is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin ; dimers and stabilizes microtubules by preventing depolymerization .", "label": "", "metadata": {}, "score": "64.13382"}
{"text": "This ; leads to the production of microtubule bundles without normal function and to the stabilization of ; microtubules , which results in the inhibition of mitosis in cells .", "label": "", "metadata": {}, "score": "64.191444"}
{"text": "The number of cells positively stained with cleaved caspase-3 was counted in 200 cells per group , and the results are shown as the average\u00b1standard deviation from two experiments .", "label": "", "metadata": {}, "score": "64.25392"}
{"text": "Mechanism of Action : 13 Target : microtubule dynamics Action : inhibitor FDA : Eribulin inhibits the growth phase of microtubules without affecting the shortening phase and sequesters ; tubulin into nonproductive aggregates .", "label": "", "metadata": {}, "score": "64.346085"}
{"text": "Inhibition of mTOR by everolimus has been shown ; to reduce cell proliferation , angiogenesis , and glucose uptake in in vitro and/or in vivo studies . ; Constitutive activation of the PI3K / Akt / mTOR pathway can contribute to endocrine resistance in breast cancer .", "label": "", "metadata": {}, "score": "64.37418"}
{"text": "Progression - free Survival for Participants With HER2-positive Tumors [ Time Frame : Up to 5 years ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "64.45754"}
{"text": "This indication is based on demonstration of an ; improvement in pathological complete response rate .No data are ; available demonstrating improvement in event - free survival or overall ; survival .", "label": "", "metadata": {}, "score": "64.48657"}
{"text": "G1/S phase regulatory molecules are ectopically expressed in radioresistant breast cancer cells .While many deregulated signaling pathways , including PI3 K , NFKB , and the MAPK pathways are involved in signaling radiation resistance [ 65 ] , the role played by the G1/S phase regulatory machinery phase in radiation resistance is unclear .", "label": "", "metadata": {}, "score": "64.53551"}
{"text": "Experimental : Arm I ( lapatinib ) .Patients receive 1500 mg lapatinib ditosylate PO QD on days 1 - 28 and fulvestrant IM on days 1 ( 500 mg ) and 15 ( 250 mg ) of course 1 and on day 1 ( 250", "label": "", "metadata": {}, "score": "64.55159"}
{"text": "The safety and efficacy of Aredia in the treatment of hypercalcemia associated with ; hyperparathyroidism or with other non - tumor - related conditions has not been established .", "label": "", "metadata": {}, "score": "64.64693"}
{"text": "In vitro studies also suggest that inhibition of osteoclast activity ; contributes to inhibition of bone resorption .In animal studies , at doses recommended for the treatment of ; hypercalcemia , Aredia inhibits bone resorption apparently without inhibiting bone formation and ; mineralization .", "label": "", "metadata": {}, "score": "64.93816"}
{"text": "Cyclin D1 overexpression is more often found in tumors with wild type p53 , higher grades of differentiation , and expression of ER or PR [ 29 - 32 ] .", "label": "", "metadata": {}, "score": "65.07039"}
{"text": "PubMed Central PubMed View Article .Reddy HK , Mettus RV , Rane SG , Grana X , Litvin J , Reddy EP : Cyclin - dependent kinase 4 expression is essential for neu - induced breast tumorigenesis .", "label": "", "metadata": {}, "score": "65.13563"}
{"text": "Knowledge Center .Read our more detailed articles about specific areas of medicine , conditions , nutrition and forms of treatment .Selecting the optimal treatment for postmenopausal patients with hormone receptor - positive metastatic breast cancer remains a challenge .", "label": "", "metadata": {}, "score": "65.143"}
{"text": "The difference in prognostic factors between early recurrence and late recurrence in estrogen receptor - positive breast cancer : nodal stage differently impacts early and late recurrence .", "label": "", "metadata": {}, "score": "65.214836"}
{"text": "G1/S phase regulatory molecules are ectopically expressed in radioresistant breast cancer cells .( A ) Non - transformed human mammary epithelial cells ( MCF10A ) and ER - PR - HER2- human breast cancer cell lines ( HCC1806 , HS578 , MDA - MB-231 & MDA - MB-468 ) were irradiated at 2 Gy .", "label": "", "metadata": {}, "score": "65.3847"}
{"text": "In accordance with cleaved caspase-3 immunocytochemisty , higher levels of cleaved PARP were detected in MCF10A ( 6 to 11 fold changes ) cells silenced for CDK4 compared to vector control .", "label": "", "metadata": {}, "score": "65.39253"}
{"text": "Fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1 , and then on Day 1 of each subsequent 28 day cycle .Drug : Placebo .", "label": "", "metadata": {}, "score": "65.54463"}
{"text": "Mechanism of Action : 13 Target : nuclear receptors in estrogen - responsive tissues Action : reduce the ; elevated levels of gonadotropins FDA : Endogenous estrogens are largely responsible for the development and maintenance of the ; female reproductive system and secondary sexual characteristics .", "label": "", "metadata": {}, "score": "65.66034"}
{"text": "Unlike biological knockdown , levels of cleaved PARP did not increase in MCF10A pLKO.1 cells treated with PD0332991 .Instead , high levels of cleaved PARP ( 2 to 3 fold ) were detected in MDA - MB-468 pLKO.1 cells treated with PD0332991 compared to untreated cells .", "label": "", "metadata": {}, "score": "65.841995"}
{"text": "10.1016/S0197 - 0186(02)00174 - 2 PubMed View Article .Berthet C , Kaldis P : Cell - specific responses to loss of cyclin - dependent kinases .", "label": "", "metadata": {}, "score": "65.86574"}
{"text": "In contrast , all subtypes respond equally well to radiation [ 15 ] .Regardless of treatment , ER - PR - HER2- or ER - PR - HER2 + breast cancers are more likely to recur upon breast conserving therapies or following mastectomy and radiation [ 16 - 19 ] .", "label": "", "metadata": {}, "score": "65.87738"}
{"text": "Goto H , Tomono Y , Ajiro K , Kosako H , Fujita M , Sakurai M , Okawa K , Iwamatsu A , Okigaki T , Takahashi T , Inagaki M : Identification of a novel phosphorylation site on histone H3 coupled with mitotic chromosome condensation .", "label": "", "metadata": {}, "score": "65.96059"}
{"text": "The BrdU assay was used to detect cells in S phase and was done by pulsing cells with 20 \u03bcM BrdU ( 51 - 7581KZ ; BD Pharmingen ) 30 minutes before harvest and detecting with an anti - BrdU antibody ( NA61 ; Calbiochem ) .", "label": "", "metadata": {}, "score": "65.97777"}
{"text": "Paclitaxel induces abnormal arrays or bundles of ; microtubules throughout the cell cycle and multiple asters of microtubules during mitosis .Malady that Drug Treats : renal cell carcinoma/ renal angiomyolipoma associated with tuberous sclerosis complex/ advanced pancreatic neuroendocrine tumor .", "label": "", "metadata": {}, "score": "66.12335"}
{"text": "A unirradiated control was also collected .A LSRII flow cytometer ( BD ) was used to read each sample .Compensation was performed using Anti - Mouse Ig , \u03ba / Negative Control ( FBS ) Compensation Particles Set ( BD , 552843 ) and samples were analyzed using Flowjo v7.6.5 and v10.4 ( Tree Star ) .", "label": "", "metadata": {}, "score": "66.14029"}
{"text": "Sismondi P .... Defabiani E. .Breast cancer is associated with loss of the c - kit oncogene product .Natali P.G ....Ullrich A. .", "label": "", "metadata": {}, "score": "66.29592"}
{"text": "The trial had a primary endpoint of PFS and secondary endpoints of objective response rate , overall survival ( OS ) , safety , and results of biomarker studies .", "label": "", "metadata": {}, "score": "66.37206"}
{"text": "Estrogen receptor ; 2 .Estrogen receptor beta .Mechanism of Action : 13 Target : estrogenic pathways Action : can be an activator or antooagonist FDA : Decreases in estrogen levels after oophorectomy or menopause lead to increases in bone resorption and ; accelerated bone loss .", "label": "", "metadata": {}, "score": "66.38443"}
{"text": "Regrettably , the defining characteristic of triple negative breast cancers ( a subtype of basal breast cancers ) is the absence of ER , PR and HER2 , rendering those cancers insensitive to some of the most effective therapies [ 4 ] .", "label": "", "metadata": {}, "score": "66.67023"}
{"text": "10.1245/s10434 - 011 - 1669 - 4 PubMed View Article .Hooning MJ , Botma A , Aleman BM , Baaijens MH , Bartelink H , Klijn JG , Taylor CW , van Leeuwen FE : Long - term risk of cardiovascular disease in 10-year survivors of breast cancer .", "label": "", "metadata": {}, "score": "66.69092"}
{"text": "Exemestane has no effect on other ; enzymes involved in the steroidogenic pathway up to a concentration at least 600 times higher than that inhibiting ; the aromatase enzyme .", "label": "", "metadata": {}, "score": "66.76796"}
{"text": "treatment may consist of radiation , lumpectomy , mastectomy , chemotherapy and hormone therapy .men can have breast cancer , too , but the number of cases is small .", "label": "", "metadata": {}, "score": "66.79047"}
{"text": "Pictures were taken at a 65\u00d7 magnification .( B )The number of cells positively stained with \u03b3 - H2AX was counted in 200 cells per group , and the results are shown as the average\u00b1standard deviation from two experiments .", "label": "", "metadata": {}, "score": "66.85325"}
{"text": "CDK : .Cyclin - dependent kinase .Gy : .Gray .Declarations .Acknowledgements .We would like to thank Dr. Rita Nahta for various Her2 + breast cancer cell lines , and Dr. Jing Chen for 293 T cells and helper plasmids .", "label": "", "metadata": {}, "score": "66.93644"}
{"text": "Additional file 2 represents a preliminary experiment with a wider range of timepoints ( up to 48 hours post - irradiation ) , to establish whether \u03b3 - H2AX foci were detected in non - irradiated cells ( basal ) or following irradiation with 2 Gy .", "label": "", "metadata": {}, "score": "67.02922"}
{"text": "Drug : Fulvestrant .Fulvestrant 500 mg given intramuscularly at cycle 1 day 1 , cycle 1 day 15 and at day 1 at each cycle thereafter .", "label": "", "metadata": {}, "score": "67.03105"}
{"text": "Drug : Fulvestrant .Fulvestrant 500 mg given intramuscularly at cycle 1 day 1 , cycle 1 day 15 and at day 1 at each cycle thereafter .", "label": "", "metadata": {}, "score": "67.03105"}
{"text": "In ; premenopausal women with metastatic breast cancer , NOLVADEX is an alternative to ; oophorectomy or ovarian irradiation .The decision regarding therapy with NOLVADEX for the reduction in breast cancer ; incidence should be based upon an individual assessment of the benefits and risks of ; NOLVADEX therapy .", "label": "", "metadata": {}, "score": "67.24306"}
{"text": "Knockdown of CDK4 results in reduced phosphorylation of BAD ( ser136 ) and upregulation of protein phosphatase type 2A ( PP2A ) .To assess why cells knocked down for CDK4 are prone to apoptosis upon irradiation , we performed a screen of various Bcl family members , with antibodies against the phosphorylated forms of those proteins , as well as total protein levels ( Figure 5 A ) .", "label": "", "metadata": {}, "score": "67.26654"}
{"text": "Pts continued until disease progression , unacceptable toxicity , or consent withdrawal and were followed for tumor assessments every 2 months .Results : A total of 165 pts were randomized in this Phase II study ; 66 pts in Part 1 and 99 pts in Part 2 .", "label": "", "metadata": {}, "score": "67.33661"}
{"text": "10.1128/MCB.00253 - 09 PubMed Central PubMed View Article .Felsher DW , Bishop JM : Transient excess of MYC activity can elicit genomic instability and tumorigenesis .", "label": "", "metadata": {}, "score": "67.51309"}
{"text": "Breast Cancer Res Treat 2010 , 124 : 187 - 194 .10.1007/s10549 - 010 - 1135 - 1 PubMed View Article .J Clin Oncol 2008 , 26 : 2373 - 2378 .", "label": "", "metadata": {}, "score": "67.76035"}
{"text": "ICI 182,780 .ZD9238 .Other : Placebo .Given PO .Other Name : PLCB .Other : Laboratory Biomarker Analysis .Correlative studies .", "label": "", "metadata": {}, "score": "67.80243"}
{"text": "Patients will be followed up for the duration of the study .PK parameters ; Patients will be assessed up to approx .6 months after randomisation date .", "label": "", "metadata": {}, "score": "67.829956"}
{"text": "In contrast , levels of phosphorylated Bad ser136 were sharply diminished Even though dephosphorylation of Bad in serine 136 is associated with apoptosis , we observe increased phosphorylation in irradiated shCDK4 MCF10A cells .", "label": "", "metadata": {}, "score": "67.856674"}
{"text": "Briefly , cells were plated in regular medium at 50 % confluence on day 1 .This was followed by changing into medium containing 5 \u03bcg / ml polybrene and infection of cells by adding undiluted shRNA lentiviral particles to the culture on day 2 .", "label": "", "metadata": {}, "score": "67.869385"}
{"text": "10.1016/j.ejca.2008.09.034 PubMed View Article .JAMA 2006 , 295 : 2492 - 2502 .10.1001/jama.295.21.2492 PubMed View Article .Lund MJ , Trivers KF , Porter PL , Coates RJ , Leyland - Jones B , Brawley OW , Flagg EW , O'Regan RM , Gabram SG , Eley JW : Race and triple negative threats to breast cancer survival : a population - based study in Atlanta , GA .", "label": "", "metadata": {}, "score": "67.92461"}
{"text": "All patients received single - agent LY2835219 daily until disease progression , death , or development of unacceptable toxicity .The results translated into an overall response rate of 19 % , clinical benefit rate of 48.9 % , and disease control rate of 70.2 % .", "label": "", "metadata": {}, "score": "68.087265"}
{"text": "IC 50 of irradiation in breast cancer cell lines with CDK2 or CDK4 knockdown .1 The p value is based on the comparisons with pLKO.1 group within each cell line .", "label": "", "metadata": {}, "score": "68.133965"}
{"text": "Mechanism of Action : 13 Target : steroidal aromatase Action : inactivator FDA : Breast cancer cell growth may be estrogen - dependent .Aromatase is the principal enzyme that converts ; androgens to estrogens both in pre- and postmenopausal women .", "label": "", "metadata": {}, "score": "68.15829"}
{"text": "DrugBank Targets : 11 1 .Receptor tyrosine - protein kinase erbB-2 ; 2 .Epidermal growth factor receptor ; 3 . Complement C1r subcomponent ; 4 .", "label": "", "metadata": {}, "score": "68.22295"}
{"text": "The mTOR pathway is dysregulated in several human cancers .Everolimus binds to an intracellular ; protein , FKBP-12 , resulting in an inhibitory complex formation with mTOR complex 1 ( mTORC1 ) and thus inhibition of ; mTOR kinase activity .", "label": "", "metadata": {}, "score": "68.28862"}
{"text": "( 1.3 ) adults with renal angiomyolipoma and tuberous sclerosis complex ( TSC ) , not requiring immediate surgery .The effectiveness of AFINITOR in the treatment of renal angiomyolipoma is based on an analysis of durable objective responses in patients treated for a median of 8.3 months .", "label": "", "metadata": {}, "score": "68.30052"}
{"text": "( 1.1 ) adults with progressive neuroendocrine tumors of pancreatic origin ( PNET ) that are unresectable , locally advanced or metastatic .AFINITOR is not indicated for the treatment of patients with functional carcinoid tumors .", "label": "", "metadata": {}, "score": "68.364265"}
{"text": "Phase 3 .Tech Support & FAQs .Answers to questions you may have can be found in the inhibitor handling instructions .Topics include how to prepare stock solutions , how to store inhibitors , and issues that need special attention for cell - based assays and animal experiments .", "label": "", "metadata": {}, "score": "68.398026"}
{"text": "10.1016/j.biochi.2003.09.004 PubMed View Article .Mumby M : PP2A : unveiling a reluctant tumor suppressor .Cell 2007 , 130 : 21 - 24 .", "label": "", "metadata": {}, "score": "68.44063"}
{"text": "In addition , paclitaxel induces abnormal arrays or bundles of microtubules ; throughout the cell cycle and multiple asters of microtubules during mitosis . ; Following intravenous administration of paclitaxel , paclitaxel plasma concentrations declined in a ; biphasic manner .", "label": "", "metadata": {}, "score": "68.735146"}
{"text": "Based on the results from the initial experiment , cells were irradiated with 0 , 2 , and 4 Gy , and analyzed 48 hours post - irradiation .", "label": "", "metadata": {}, "score": "68.853615"}
{"text": "Although cells expressing shCDK2 incorporated BrdU at a lower extent than other groups ( Additional file 1 A ) , no differences were found when using Ki67 as an independent marker of proliferation ( Additional file 1 B ) .", "label": "", "metadata": {}, "score": "68.88798"}
{"text": "Silencing the catalytic subunit of PP2A does not lead to increased PARP cleavage in irradiated cells silenced for CDK4 .To investigate whether silencing of PP2A reverses apoptosis in irradiated cells silenced for CDK4 , the PP2A catalytic unit was knocked down using siRNAs ( Figure 6 ) .", "label": "", "metadata": {}, "score": "68.94076"}
{"text": "Kuru B : Prognostic factors for locoregional recurrence and survival in stage IIIC breast carcinoma : impact of adjuvant radiotherapy .Singapore Med J 2011 , 52 : 289 - 298 .", "label": "", "metadata": {}, "score": "69.20635"}
{"text": "Nuclei were counter - stained with DAPI .The number of cells positively stained with BrdU was counted in 200 cells per group , and the results are shown as the average\u00b1standard deviation from two independent experiments .", "label": "", "metadata": {}, "score": "69.47716"}
{"text": "10.1038/sj.onc.1210243 PubMed View Article .Berthet C , Kaldis P : Cdk2 and Cdk4 cooperatively control the expression of Cdc2 .Cell division 2006 , 1 : 10 .", "label": "", "metadata": {}, "score": "69.61282"}
{"text": "PubMed .Breast cancer research : BCR 2009 , 11 : R77 .10.1186/bcr2419 PubMed Central PubMed View Article .Begg AC , Stewart FA , Vens C : Strategies to improve radiotherapy with targeted drugs .", "label": "", "metadata": {}, "score": "69.71578"}
{"text": "Xin M , Deng X : Protein phosphatase 2A enhances the proapoptotic function of Bax through dephosphorylation .J Biol Chem 2006 , 281 : 18859 - 18867 .", "label": "", "metadata": {}, "score": "69.72008"}
{"text": "The G1 phase CDKs , ( CDK2 , CDK4 , and CDK6 ) display specific functions in terms of development and redundant functions in terms of cell cycle regulation [ 23 , 24 , 83 ] .", "label": "", "metadata": {}, "score": "69.78111"}
{"text": "Low affinity immunoglobulin gamma Fc region receptor II - b ; 11 .Low affinity immunoglobulin gamma Fc region receptor II - c ; 12 .", "label": "", "metadata": {}, "score": "69.79702"}
{"text": "To find out what is responsible for the dephosphorylation of Bad at ser136 , we detected the relative protein levels of the protein phosphatases PP1\u03b1 , PP2A , and PP2B. As shown in Figure 5 B , the basal levels of PP2A at time 0 were immediately upregulated in MCF10A and MDA - MB-231 cells lacking CDK4 upon irradiation , and the levels remained upregulated .", "label": "", "metadata": {}, "score": "69.979"}
{"text": "Immunocytochemistry assays .Immunofluorescence was performed by following our published protocols [ 73 , 97 ] .Cells were plated at 4\u00d710 4 per well into two - well tissue culture chamber slides and received 2 Gy irradiation after cells attached .", "label": "", "metadata": {}, "score": "70.03302"}
{"text": "This data indicates that downregulation of PP2A does not reverse apoptosis in cells knocked down for CDK4 .We conclude that apoptosis in irradiated cells silenced for CDK4 does not involve the PP2A catalytic subunit .", "label": "", "metadata": {}, "score": "70.13146"}
{"text": "Original Secondary Outcome Measures ICMJE .Not Provided .Current Other Outcome Measures ICMJE ( submitted : March 4 , 2015 ) .Progression - free Survival for Participants With HER2-negative Tumors [ Time Frame : Up to 5 years ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "70.18474"}
{"text": "Survival analysis is ongoing , but the current estimate of median PFS is 9.1 months , she added .This is pretty impressive data , \" press briefing moderator Patricia LoRusso , DO , of the Karmanos Cancer Institute in Detroit , said of the CKD-4/6 trials . \"", "label": "", "metadata": {}, "score": "70.33273"}
{"text": "Cells were counterstained with DAPI .Frequencies of the various phenotypes are done by counting the number of antigen - positive cells divided by the total number of cells ; unless otherwise indicated , we count at least 200 cells per group .", "label": "", "metadata": {}, "score": "70.3542"}
{"text": "Improvement in diseaserelated symptoms and overall survival in patients with SEGA and TSC has not been demonstrated .DrugBank Targets : 11 Serine / threonine - protein kinase mTOR .", "label": "", "metadata": {}, "score": "70.64865"}
{"text": "No new or unexpected adverse events occurred during the trial .The most common adverse events in the combination arm were neutropenia , leukopenia , fatigue , and anemia .", "label": "", "metadata": {}, "score": "70.7743"}
{"text": "BKM120 100 mg , daily oral capsules .Active Comparator : Placebo and fulvestrant .BKM120 matching placebo given daily and fulvestrant 500 mg given intramuscularly at cycle 1 day 1 , cycle 1 day 15 and at day 1 at each cycle thereafter .", "label": "", "metadata": {}, "score": "70.86046"}
{"text": "Thus , raloxifene is an estrogen ; agonist / antagonist , commonly referred to as a selective estrogen receptor modulator ( SERM ) . ; Raloxifene decreases resorption of bone and reduces biochemical markers of bone turnover to the ; premenopausal range .", "label": "", "metadata": {}, "score": "70.94589"}
{"text": "Proportion of patients with PIK3CA mutant tumors [ Time Frame : until disease progression , up to 1 year ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "70.964905"}
{"text": "Hung J.H. .Prognostic Significance of Ki-67 in Chemotherapy - naive Breast Cancer Patients with 10-year Follow - up .Nishimiya H ....Masahiko W. .", "label": "", "metadata": {}, "score": "71.024414"}
{"text": "PubMed .Wang TC , Cardiff RD , Zukerberg L , Lees E , Arnold A , Schmidt EV : Mammary hyperplasia and carcinoma in MMTV - cyclin D1 transgenic mice .", "label": "", "metadata": {}, "score": "71.25621"}
{"text": "The relative percentage of cells in each phase of the cell cycle was assessed by measuring DNA content using flow cytometry ( Figure 3 ) , while a flow cytometry - based BrdU assay measured percentage of replicating cells post - irradiation ( Table 3 ) .", "label": "", "metadata": {}, "score": "71.314575"}
{"text": "For the colony forming assay , a dose response analysis was conducted , in which the dose response relationship was assumed to be the commonly used four parameter logistic function [ 112 ] .", "label": "", "metadata": {}, "score": "71.56653"}
{"text": "ARM I : Patients receive lapatinib ditosylate orally ( PO ) once daily ( QD ) on days 1 - 28 and fulvestrant intramuscularly ( IM ) on days 1 and 15 of course 1 and on day 1 of each subsequent course .", "label": "", "metadata": {}, "score": "71.787506"}
{"text": "\" Will that translate into even better outcomes for patients with hormonal therapy ?Only time will tell .\" MedPageToday is a trusted and reliable source for clinical and policy coverage that directly affects the lives and practices of health care professionals .", "label": "", "metadata": {}, "score": "71.80835"}
{"text": "The ; effectiveness of Aredia was demonstrated primarily in patients with serum alkaline phosphatase e\"3 times ; the upper limit of normal .Aredia therapy in patients with Paget s disease has been effective in reducing ; serum alkaline phosphatase and urinary hydroxyproline levels by e\"50 % in at least 50 % of patients , and by ; e\"30 % in at least 80 % of patients .", "label": "", "metadata": {}, "score": "71.90004"}
{"text": "Indications and Usage : 13 Hypercalcemia of Malignancy ; Aredia , in conjunction with adequate hydration , is indicated for the treatment of moderate or severe ; hypercalcemia associated with malignancy , with or without bone metastases .", "label": "", "metadata": {}, "score": "71.99809"}
{"text": "XD : Provided antibodies and designed the experiments that lead to the Western blot analyses of various apoptotic proteins .HIS : Designed the experiments in the manuscript , edited the manuscript , and established all collaborations in the manuscript .", "label": "", "metadata": {}, "score": "72.13244"}
{"text": "CAN-05 - 3945 PubMed View Article .Jirawatnotai S , Aziyu A , Osmundson EC , Moons DS , Zou X , Kineman RD , Kiyokawa H : Cdk4 is indispensable for postnatal proliferation of the anterior pituitary .", "label": "", "metadata": {}, "score": "72.58753"}
{"text": "European Organization for Research and Treatment of Cancer Quality of Life Questionnaire ( EORTC QLQ - C30 )[ Time Frame : From baseline through approximately month 10 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "72.683426"}
{"text": "The blots were then rinsed in 1X TBS - T and incubated with the appropriate horseradish peroxidase conjugated secondary antibodies at room temperature .The blots were then rinsed in 1X TBS - T and the antibody - antigen complex was visualized using Lumigen TMA-6 ( RPN2135v1 and RPN2135v2 ; GE Healthcare ) .", "label": "", "metadata": {}, "score": "72.820305"}
{"text": "Journal international du cancer 2010 , 127 : 355 - 360 .PubMed .Utsumi T , Yoshimura N , Maruta M , Takeuchi S , Ando J , Mizoguchi Y , Harada N : Correlation of cyclin D1 MRNA levels with clinico - pathological parameters and clinical outcome in human breast carcinomas .", "label": "", "metadata": {}, "score": "72.94209"}
{"text": "\u03b2 - actin was used as a loading control .Protein levels were normalized based on \u03b2 - actin , and are indicated as fold - induction relative to scrambled siRNA controls .", "label": "", "metadata": {}, "score": "72.99959"}
{"text": "Most adverse events were mild or moderate in severity .Grade 3/4 neutropenia occurred in 11 % of patients .No other grade 3/4 events occurred in more than 5 % of patients .", "label": "", "metadata": {}, "score": "73.17964"}
{"text": "Interventional .Study Phase .Phase 3 .Study Design ICMJE .Allocation : Randomized Endpoint Classification : Efficacy Study Intervention Model : Parallel Assignment Masking : Double Blind ( Subject , Caregiver , Investigator , Outcomes Assessor ) Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "73.48732"}
{"text": "Pharmacokinetic parameters of GDC-0941 and GDC-0980 : maximum concentration [ Time Frame : Cycle 1 , Day 15/16 ; Cycle 2 , Day 15 ; Cycle , 6 Day 1 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "73.49168"}
{"text": "SSZ : Developed the irradiation protocols for the radiation sensitivity and colony formation experiments .YL : Biostatistician that performed many of the statistical assays in the manuscript .", "label": "", "metadata": {}, "score": "73.816246"}
{"text": "Patients ; should be hydrated adequately throughout the treatment , but overhydration , especially in those patients ; who have cardiac failure , must be avoided .", "label": "", "metadata": {}, "score": "73.86655"}
{"text": "Patients should have either : ; Received prior therapy for metastatic disease , or ; Developed disease recurrence during or within six months of ; completing adjuvant therapy .", "label": "", "metadata": {}, "score": "74.03882"}
{"text": "MalaCards based summary : Breast Cancer , also known as breast carcinoma , is related to lung cancer and familial breast cancer , and has symptoms including autosomal dominant inheritance , heterogeneous and breast carcinoma .", "label": "", "metadata": {}, "score": "74.03978"}
{"text": "In addition to loss of estrogen , this imbalance between resorption and ; formation may be due to age - related impairment of osteoblasts or their precursors .", "label": "", "metadata": {}, "score": "74.35484"}
{"text": "In the normal state , CDK-4/6 facilitates progression from the growth phase ( G1 ) of the cell cycle into the S - phase , which is associated with DNA synthesis .", "label": "", "metadata": {}, "score": "74.422005"}
{"text": "6 months after randomisation date .Patient reported outcomes for global health status / QOL [ Time Frame : Cycle 1 day 1 , cycle 1 day 15 , 6 weeks after randomisation and then every 8 weeks until end of treatment ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "74.42763"}
{"text": "Type , frequency and severity of adverse events [ Time Frame : at minimum at each study visit and up to approx .10 months ] [ Designated as safety issue : Yes ] .", "label": "", "metadata": {}, "score": "74.43024"}
{"text": "MGMT activity of BG - treated cells is undetectable 2 hours after the addition of the inhibitor PHA-848125 and remained essentially undetectable up to the end of the assay .", "label": "", "metadata": {}, "score": "74.68594"}
{"text": "Additional file 1 represents two preliminary experiments with a wider range of timepoints , to establish whether DNA replication was affected up to 48 hours post - irradiation .", "label": "", "metadata": {}, "score": "74.90747"}
{"text": "Santamaria D , Barriere C , Cerqueira A , Hunt S , Tardy C , Newton K , Caceres JF , Dubus P , Malumbres M , Barbacid M : Cdk1 is sufficient to drive the mammalian cell cycle .", "label": "", "metadata": {}, "score": "74.978355"}
{"text": "10.1016/j.clon.2010.10.001 View Article .Carey LA , Dees EC , Sawyer L , Gatti L , Moore DT , Collichio F , Ollila DW , Sartor CI , Graham ML , Perou CM : The triple negative paradox : primary tumor chemosensitivity of breast cancer subtypes .", "label": "", "metadata": {}, "score": "75.032364"}
{"text": "European Organization for Research and Treatment of Cancer breast cancer module ( EORTC QLQ BR23 ) [ Time Frame : From baseline through approximately month 10 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "75.09148"}
{"text": "The authors declare they have no competing interests .Authors ' contributions .KRH : Performed the radiation and flow cytometry experiments to detect DNA proliferation , apoptosis and DNA breaks .", "label": "", "metadata": {}, "score": "75.11952"}
{"text": "; Exemestane is an irreversible , steroidal aromatase inactivator , structurally related to the natural substrate ; androstenedione .It acts as a false substrate for the aromatase enzyme , and is processed to an intermediate that binds ; irreversibly to the active site of the enzyme , causing its inactivation , an effect also known as suicide inhibition .", "label": "", "metadata": {}, "score": "75.58777"}
{"text": "The mean percentage of the positive cells relative to no radiation is used for analyses , named fold - change to no radiation .The main goal of this data analysis is to compare the fold change between control and treatment groups at each time point , within each cell line , biomarker , and gate .", "label": "", "metadata": {}, "score": "75.73416"}
{"text": "Clinical benefit defined as partial response ( PR ) , complete response ( CR ) , or stable disease ( SD ) per modified RECIST v1.1 [ Time Frame : until disease progression , up to 1 year ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "76.01103"}
{"text": "Thymidylate is the necessary precursor of thymidine ; triphosphate , which is essential for the synthesis of DNA , so that a deficiency of this compound ; can inhibit cell division .", "label": "", "metadata": {}, "score": "76.041855"}
{"text": "M512543200 PubMed View Article .Cancer Cell 2006 , 10 : 515 - 527 .10.1016/j.ccr.2006.10.008 PubMed Central PubMed View Article .Ritz C , JC S : Bioassay Analysis using R. J. Statistics Software .", "label": "", "metadata": {}, "score": "76.30699"}
{"text": "S6K1 is a substrate of ; mTORC1 and phosphorylates the activation domain 1 of the estrogen receptor which results in ligand - independent ; activation of the receptor .", "label": "", "metadata": {}, "score": "76.34262"}
{"text": "10.1128/MCB.23.18.6350 - 6362.2003 PubMed Central PubMed View Article .Klumpp S , Selke D , Krieglstein J : Protein phosphatase type 2C dephosphorylates BAD .", "label": "", "metadata": {}, "score": "76.384995"}
{"text": "--- Our top categories - Alzheimer 's / Dementia - Breast Cancer - Cancer / Oncology - Diabetes - Ebola - HIV / AIDS - Infectious Diseases - Multiple Sclerosis - Nutrition / Diet - Parkinson 's Disease - Stem Cell Research --- View all categories .", "label": "", "metadata": {}, "score": "76.39488"}
{"text": "Phosphorylation of histone 3 at Ser10 , Ser28 and Thr11 is correlated with chromosome condensation during mitosis [ 67 , 68 ] and is regarded as an indicator of mitosis .", "label": "", "metadata": {}, "score": "76.44156"}
{"text": "10.1038/nrc2696 PubMed Central PubMed View Article .Iaquinta PJ , Lees JA : Life and death decisions by the E2F transcription factors .Curr Opin Cell Biol 2007 , 19 : 649 - 657 .", "label": "", "metadata": {}, "score": "76.490265"}
{"text": "Elizabeth Mittendorf , MD , PhD , of the University of Texas MD Anderson Cancer Center in Houston pointed out that the trial was not designed to evaluate OS .", "label": "", "metadata": {}, "score": "76.75344"}
{"text": "An analysis limited to the ER - positive subset yielded an overall response rate of 25 % , clinical benefit rate of 61.1 % , and disease control rate of 80.8 % .", "label": "", "metadata": {}, "score": "77.11086"}
{"text": "Radioresistance can be a consequence of a deregulated cell cycle , altered frequencies of apoptosis , or altered frequencies of DNA repair [ 58 - 60 ] .", "label": "", "metadata": {}, "score": "77.285095"}
{"text": "\u03b2 - actin was used as a loading control .( PDF 324 KB ) .Authors ' original submitted files for images .Below are the links to the authors ' original submitted files for images .", "label": "", "metadata": {}, "score": "77.2905"}
{"text": "Stage IV breast cancer ( using American Joint Committee on Cancer [AJCC ] criteria , 6th edition ) , or locally advanced ( stage III ) breast cancer not considered amenable to curative therapy .", "label": "", "metadata": {}, "score": "77.33812"}
{"text": "Commitment to apoptosis was detected by using an antibody against cleaved caspase-3 ( 9661 , Cell Signaling ) .DNA breaks were detected using an antibody against phosphorylated histone 2A variant X ( \u03b3 - H2AX ) ( ab2893 , Abcam ) .", "label": "", "metadata": {}, "score": "77.36629"}
{"text": "Pregnancy , lactation , or breastfeeding .Known untreated or active central nervous system ( CNS ) metastases Other protocol - defined inclusion / exclusion criteria may apply .", "label": "", "metadata": {}, "score": "77.43181"}
{"text": "Vigorous saline hydration , an ; integral part of hypercalcemia therapy , should be initiated promptly and an attempt should be made to ; restore the urine output to about 2 L / day throughout treatment .", "label": "", "metadata": {}, "score": "77.61745"}
{"text": "Cancer Treat Rev 2010 , 36 ( Suppl 3):S80-S86 .PubMed View Article .Irvin WJ Jr , Carey LA : What is triple - negative breast cancer ?", "label": "", "metadata": {}, "score": "77.99168"}
{"text": "Hope S. Rugo , MD .Professor of Medicine and Director of the Breast Oncology , Clinical Trials , and Education Program , University of California San Francisco Comprehensive Cancer Center , San Francisco , California .", "label": "", "metadata": {}, "score": "78.160904"}
{"text": "The primary endpoint was investigator assessed progression - free survival ( PFS ) defined as time from randomization to objective progression or death .Secondary endpoints included objective response rate , overall survival , safety , and correlative biomarker studies .", "label": "", "metadata": {}, "score": "78.49617"}
{"text": "Graphical network of the top 20 diseases related to Breast Cancer : .Jump to section Aliases & Classifications Anatomical Context Animal Models Compounds Drugs & Therapeutics Expression Genes Genetic Tests GO Terms Pathways Publications Related Diseases Sources Summaries Symptoms Variations Top Bottom .", "label": "", "metadata": {}, "score": "78.50256"}
{"text": "Bad is a proapoptotic member of the Bcl-2 family that promotes cell death by displacing Bax from binding to Bcl-2 and Bcl - xL [ 78 ] .", "label": "", "metadata": {}, "score": "79.08099"}
{"text": "Not Provided .Study Type ICMJE .Interventional .Study Phase .Phase 3 .Study Design ICMJE .Allocation : Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Parallel Assignment Masking : Double Blind ( Subject , Caregiver , Investigator )", "label": "", "metadata": {}, "score": "79.235596"}
{"text": "women who have family members with breast or ovarian cancer may wish to be tested . symptoms of breast cancer may include a lump in the breast , a change in size or shape of the breast or discharge from a nipple .", "label": "", "metadata": {}, "score": "79.48222"}
{"text": "[ Time Frame : up to approx . 8.3 months ] [ Designated as safety issue : No ] .Proportion of patients with a best overall response of complete response ( CR ) or partial response ( PR ) or stable disease ( SD ) lasting more than 24 weeks as defined in RECIST 1.1 .", "label": "", "metadata": {}, "score": "79.81978"}
{"text": "Biomarkers from tissue including genes , proteins , and RNA expression .Euro Quality of Life ( EQ-5D)- Health State Profile Utility Score [ Time Frame : From baseline through approximately month 10 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "79.830986"}
{"text": "Complement C1q subcomponent subunit B ; 6 .Complement C1q subcomponent subunit C ; 7 .Complement C1s subcomponent ; 8 .High affinity immunoglobulin gamma Fc receptor I ; 9 .", "label": "", "metadata": {}, "score": "80.437035"}
{"text": "CCR-06 - 1109 PubMed View Article .Int J Radiat Oncol Biol Phys 2010 , 78 : 799 - 803 .10.1016/j.ijrobp.2009.08.081 PubMed View Article .", "label": "", "metadata": {}, "score": "80.77417"}
{"text": "Eastern Cooperative Oncology Group ( ECOG ) Performance Status of 0 or 1 .Patients must have measurable disease by RECIST v1.1 or bone - only disease .", "label": "", "metadata": {}, "score": "80.834366"}
{"text": "10.1007/s10549 - 008 - 9926 - 3 PubMed View Article .J Clin Oncol 2007 , 25 : 3259 - 3265 .10.1200/JCO.2007.11.4991 PubMed View Article .", "label": "", "metadata": {}, "score": "80.861465"}
{"text": "Allocation : Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Parallel Assignment Masking : Double Blind ( Subject , Caregiver , Investigator , Outcomes Assessor ) Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "81.495186"}
{"text": "Indications and Usage : 13 Paclitaxel Injection , USP is indicated as subsequent therapy for the treatment of advanced carcinoma of ; the ovary .As first - line therapy , Paclitaxel Injection , USP is indicated in combination with cisplatin .", "label": "", "metadata": {}, "score": "81.539246"}
{"text": "Eastern Cooperative Oncology Group ( ECOG ) ( Zubrod ) performance status 0 - 2 .Absence of pending visceral crisis , in the opinion of the treating physician .", "label": "", "metadata": {}, "score": "81.78337"}
{"text": "Estrogens act through binding to nuclear receptors in estrogen - responsive tissues .To date , ; two estrogen receptors have been identified .These vary in proportion from tissue to tissue . ; Circulating estrogens modulate the pituitary secretion of the gonadotropins , luteinizing ; hormone ( LH ) and FSH , through a negative feedback mechanism .", "label": "", "metadata": {}, "score": "81.80659"}
{"text": "Duration of Response [ Time Frame : Baseline up to approximately 10 months ] [ Designated as safety issue : No ] .Time from the first documentation of objective tumor response to objective tumor progression or death due to any cause .", "label": "", "metadata": {}, "score": "81.90933"}
{"text": "Proportion of patients with best overall response of complete response ( CR ) or partial response ( PR ) based according to RECIST 1.1 .Patients will be followed up for the duration of the study and for an expected average of every 8 weeks after randomisation .", "label": "", "metadata": {}, "score": "81.91247"}
{"text": "Cells were irradiated at 2 Gy , pulsed with BrdU ( added at a final concentration of 10 \u03bcM 30 min prior to harvest ) and harvested at various time points ( 6 , 12 , and 24 hours ) .", "label": "", "metadata": {}, "score": "82.32979"}
{"text": "[ Time Frame : Interval from randomization until disease progression or death , whichever occurs first , assessed up to 5 years ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "82.356476"}
{"text": "Response was defined by the Response Evaluation Criteria in Solid Tumors ( RECIST ) .A responding participant had either a Complete Response ( disappearance of all target lesions ) or Partial Response ( 30 % decrease in sum of longest diameter of target lesions ) .", "label": "", "metadata": {}, "score": "82.53897"}
{"text": "NCT Number ICMJE .NCT00390455 .Other Study ID Numbers ICMJE .NCI-2009 - 00475 , NCI-2009 - 00475 , CDR0000510452 , CALGB-40302 , CALGB 40302 , CALGB-40302 , U10CA180821 , U10CA031946 Abstract .", "label": "", "metadata": {}, "score": "82.659805"}
{"text": "3 Year Probability of Participant Survival [ Time Frame : From baseline through 3 years ] [ Designated as safety issue : Yes ] .Probability of survival 3 years after randomization .", "label": "", "metadata": {}, "score": "82.86639"}
{"text": "The significance levels are set at 0.05 for all tests .The SAS statistical package V9.3 ( SAS Institute , Inc. , Cary , North Carolina ) is used for data managements and analyses .", "label": "", "metadata": {}, "score": "83.09589"}
{"text": "Blocking CDK4 activity may lead to effective breast cancer treatments .Wikipedia : 64 Breast cancer is cancer that develops from breast tissue .Signs of breast cancer may include a lump in ... more ... .", "label": "", "metadata": {}, "score": "83.3243"}
{"text": "Given until objective progression , symptomatic deterioration , unacceptable toxicity , death , or withdrawal of consent , whichever occurs first .Contact information is only displayed when the study is recruiting subjects .", "label": "", "metadata": {}, "score": "83.60139"}
{"text": "Prior fulvestrant therapy is prohibited .Patients must be postmenopausal women , defined as a woman fulfilling any of the following criteria : .History of bilateral oophorectomy ; or .", "label": "", "metadata": {}, "score": "83.728615"}
{"text": "Probability of survival one year after randomization .2 Year Probability of Participant Survival [ Time Frame : From baseline through 2 years ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "83.83715"}
{"text": "All cell lines were cultured at 37 \u00b0 C in a humidified atmosphere ( 5 % CO 2 ) .Colony forming assay .Two thousand five hundred cells were plated per well in a 6-well culture plate or one thousand cells were plated per well in a 12-well cell culture plate ( Day 0 ) in triplicates .", "label": "", "metadata": {}, "score": "84.347046"}
{"text": "The y axis represents percentage colony formation relative to unirradiated cells of the respective groups ; the x axis represents the various radiation doses .The IC 50 and statistical significance are presented in Table 2 .", "label": "", "metadata": {}, "score": "84.88102"}
{"text": "T - tests were done in Excel .The statistical significance level of all tests was set at 0.05 .For the flow cytometry assays ( DNA content and BrdU ) the data was aligned by the six - hour gates .", "label": "", "metadata": {}, "score": "85.05186"}
{"text": "Study Arm ( s ) .Experimental : Arm A .Given until objective progression , symptomatic deterioration , unacceptable toxicity , death , or withdrawal of consent , whichever occurs first .", "label": "", "metadata": {}, "score": "86.03375"}
{"text": "Patients will be followed up for the duration of the study and for an expected average of every 8 weeks after randomisation .Overall response rate ( ORR )", "label": "", "metadata": {}, "score": "86.22859"}
{"text": "HPO human phenotypes related to Breast Cancer : .Jump to section Aliases & Classifications Anatomical Context Animal Models Compounds Drugs & Therapeutics Expression Genes Genetic Tests GO Terms Pathways Publications Related Diseases Sources Summaries Symptoms Variations Top Bottom .", "label": "", "metadata": {}, "score": "86.237076"}
{"text": "The higher value of IC50 , the higher the resistance .A proper data transformation , Box- Cox transformation , [ 113 ] was applied to assure the fitted model meeting the statistical assumptions .", "label": "", "metadata": {}, "score": "86.53807"}
{"text": "10.1186/1756 - 0500 - 2 - 140 PubMed Central PubMed View Article .Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 , 27 : 4515 - 4521 .", "label": "", "metadata": {}, "score": "86.587494"}
{"text": "\u03b3 - H2AX foci were clearly detectable upon irradiation ( Additional file 2 A ) .Regardless of the cell line , the percentage of \u03b3 - H2AX foci decreased gradually post - irradiation in all groups and reached basal levels by 24 hours .", "label": "", "metadata": {}, "score": "86.65802"}
{"text": "[ Time Frame : up to approx . 8.3 months ] [ Designated as safety issue : No ] .PFS is defined as the time from the date of randomization until the date of the first radiologically documented disease progression or death due to any cause .", "label": "", "metadata": {}, "score": "86.75829"}
{"text": "Ascites .Pleural / pericardial effusion .Inflammatory breast cancer .Lymphangitis cutis / pulmonitis .Abdominal masses that are not confirmed and followed by imaging techniques .", "label": "", "metadata": {}, "score": "86.9287"}
{"text": "Patnaik presented results from the breast cancer subset of a phase I trial that involved a total of 132 patients with various types of solid tumors .", "label": "", "metadata": {}, "score": "87.01964"}
{"text": "Lesions that are considered non - measurable include the following : .Bone lesions ( women with bone lesions will be eligible as described above ) .", "label": "", "metadata": {}, "score": "87.655304"}
{"text": "Assistant Professor & Director , Hematology / Oncology Breast Cancer Program , UCLA 's Jonsson Comprehensive Cancer Center , Los Angeles , California .Joyce A. O'Shaughnessy , MD .", "label": "", "metadata": {}, "score": "87.92722"}
{"text": "Time from randomization to date of death due to any cause .Objective Response [ Time Frame : Baseline until approximately 10 months ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "88.1409"}
{"text": "OncLiveTV Peer Exchange reserves the right to alter or correct any error or omission in the information it provides in this video , without any obligations .", "label": "", "metadata": {}, "score": "88.44315"}
{"text": "10.3322/CA.2007.0010 PubMed View Article .Proc Natl Acad Sci USA 2001 , 98 : 10869 - 10874 .10.1073/pnas.191367098 PubMed Central PubMed View Article .", "label": "", "metadata": {}, "score": "88.86354"}
{"text": "10.1016/S1074 - 7613(00)80151-X PubMed View Article .Mol Cell Biol 2004 , 24 : 8917 - 8928 .10.1128/MCB.24.20.8917 - 8928.2004 PubMed Central PubMed View Article .", "label": "", "metadata": {}, "score": "89.04819"}
{"text": "[ Time Frame : Baseline up to approximately 10 months ] [ Designated as safety issue : No ] .CBR is defined as complete response or partial response or stable disease equal to or greater than 24 weeks according to RECIST version 1.1 recorded in the time period between randomization and disease progression or death of any cause .", "label": "", "metadata": {}, "score": "89.27274"}
{"text": "Vertebral fractures are the most common type of osteoporotic fracture in postmenopausal women . ; The biological actions of raloxifene are largely mediated through binding to estrogen receptors .", "label": "", "metadata": {}, "score": "89.44199"}
{"text": "Contact our news editors .For any corrections of factual information , or to contact our editorial team , please see our contact page .Please note : Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional .", "label": "", "metadata": {}, "score": "90.25308"}
{"text": "The online version of this article ( doi : 10 .1186/\u200b1747 - 1028 - 8 - 10 ) contains supplementary material , which is available to authorized users .", "label": "", "metadata": {}, "score": "90.28765"}
{"text": "In TSC , a genetic disorder , ; inactivating mutations in either the TSC1 or the TSC2 gene lead to hamartoma formation throughout the body .", "label": "", "metadata": {}, "score": "90.58382"}
{"text": "Jump to section Aliases & Classifications Anatomical Context Animal Models Compounds Drugs & Therapeutics Expression Genes Genetic Tests GO Terms Pathways Publications Related Diseases Sources Summaries Symptoms Variations Top Bottom Current Primary Outcome Measures ICMJE ( submitted : March 4 , 2015 ) .", "label": "", "metadata": {}, "score": "90.741425"}
{"text": "\u00a9 Hagen et al . ; licensee BioMed Central Ltd. 2013 .This article is published under license to BioMed Central Ltd. Current Secondary Outcome Measures ICMJE ( submitted : September 10 , 2013 ) .", "label": "", "metadata": {}, "score": "91.47599"}
{"text": "Western blots .Western blotting was performed according to published protocols [ 73 , 97 ] .Samples were denatured at 95 \u00b0 C for 5 min in sodium dodecyl sulfate ( SDS ) sample buffer , resolved by SDS polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes ( Bio - Rad ) .", "label": "", "metadata": {}, "score": "91.48683"}
{"text": "Genetics Home Reference : 21 Breast cancer is a disease in which certain cells in the breast become abnormal and multiply without control or order to form a tumor .", "label": "", "metadata": {}, "score": "91.6118"}
{"text": "Journal of the Royal Statistical Society Series B 1964 , 26 : 211 - 252 .Team RDC : R : A language and environment for statistical computing .", "label": "", "metadata": {}, "score": "91.71849"}
{"text": "Immunohistochemistry ( IHC ) 0 ( i.e. , negative ) , 1 + , 2 + , or 3 + levels of expression , or .", "label": "", "metadata": {}, "score": "91.88323"}
{"text": "The dephosphorylation of Bad is mainly accomplished by various protein phosphatases [ 80 - 82 ] .We speculated that Bad ser136 was being dephosphorylated through the increased activity and/or levels of a phosphatase .", "label": "", "metadata": {}, "score": "91.95083"}
{"text": "No research on humans or animals were conducted .All human cell lines were purchased from the publically available American Type Culture Collection ( ATCC ) , or obtained through collaborators .", "label": "", "metadata": {}, "score": "92.56026"}
{"text": "After an average of 8 days , cells were fixed with 75 % ethanol and stained with 1 % crystal violet , and colonies containing more than 50 cells ( established by microscopy ) were counted manually .", "label": "", "metadata": {}, "score": "92.72293"}
{"text": "Flow cytometry and analysis was repeated three times .The columns represent the percentage of cells in the G1 , S or G2/M phase and presented as average\u00b1standard deviation .", "label": "", "metadata": {}, "score": "92.87175"}
{"text": "At the end of the incubation period , cell growth is evaluated by the MTT assay .Briefly , 0.1 mg of MTT ( in 20 \u03bcL of PBS ) is added to each well and cells are incubated at 37 \u00b0 C for 4 hours .", "label": "", "metadata": {}, "score": "92.9193"}
{"text": "Original Secondary Outcome Measures ICMJE .Same as current .Current Other Outcome Measures ICMJE .Not Provided .Original Other Outcome Measures ICMJE .Not Provided .", "label": "", "metadata": {}, "score": "93.00487"}
{"text": "A responding participant had either a Complete Response ( disappearance of all target lesions ) or Partial Response ( 30 % decrease in sum of longest diameter of target lesions ) .", "label": "", "metadata": {}, "score": "93.077255"}
{"text": "A responding participant had either a Complete Response ( disappearance of all target lesions ) or Partial Response ( 30 % decrease in sum of longest diameter of target lesions ) .", "label": "", "metadata": {}, "score": "93.077255"}
{"text": "Minimally Important Difference Cut - Off [ Time Frame : From baseline through approximately month 10 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "93.08168"}
{"text": "Progression is defined as a 20 % increase in the sum of longest diameter of target lesions ( per RECIST criteria ) .Current Secondary Outcome Measures ICMJE ( submitted : March 4 , 2015 ) .", "label": "", "metadata": {}, "score": "93.726425"}
{"text": "Authors ' Affiliations .Department of Radiation Oncology , Emory University School of Medicine .Department of Medical Oncology , Emory University School of Medicine .", "label": "", "metadata": {}, "score": "93.84353"}
{"text": "10.1093/nar / gkg176 PubMed Central PubMed View Article .Science 2002 , 296 : 922 - 927 .10.1126/science.1069398 PubMed View Article .", "label": "", "metadata": {}, "score": "94.033264"}
{"text": "Getting mammograms regularly can lower the risk of dying from breast cancer .If you are 50 to 74 years old , be sure to have a screening mammogram every two years .", "label": "", "metadata": {}, "score": "94.13129"}
{"text": "Background .Breast cancer is the most common malignancy and the major cause of cancer related deaths of women in industrialized countries [ 1 ] .", "label": "", "metadata": {}, "score": "94.49898"}
{"text": "Novus Biologicals : 45 Breast cancer is a malignant tumor that originates from breast tissue cells .Although most breast cancers initiate in the cells that line the breast ducts , some begin in the breast lobules and other tissues .", "label": "", "metadata": {}, "score": "94.618454"}
{"text": "PubMed View Article .J Natl Cancer Inst 2006 , 98 : 1723 - 1731 .10.1093/jnci / djj467 PubMed Central PubMed View Article .", "label": "", "metadata": {}, "score": "94.83378"}
{"text": "Overall Survival ( OS ) [ Time Frame : Study entry to death or last follow - up , up to 5 years ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "94.84519"}
{"text": "Jump to section Aliases & Classifications Anatomical Context Animal Models Compounds Drugs & Therapeutics Expression Genes Genetic Tests GO Terms Pathways Publications Related Diseases Sources Summaries Symptoms Variations Top Bottom .", "label": "", "metadata": {}, "score": "95.00409"}
{"text": "Jump to section Aliases & Classifications Anatomical Context Animal Models Compounds Drugs & Therapeutics Expression Genes Genetic Tests GO Terms Pathways Publications Related Diseases Sources Summaries Symptoms Variations Top Bottom .", "label": "", "metadata": {}, "score": "95.00409"}
{"text": "Jump to section Aliases & Classifications Anatomical Context Animal Models Compounds Drugs & Therapeutics Expression Genes Genetic Tests GO Terms Pathways Publications Related Diseases Sources Summaries Symptoms Variations Top Bottom .", "label": "", "metadata": {}, "score": "95.00409"}
{"text": "Jump to section Aliases & Classifications Anatomical Context Animal Models Compounds Drugs & Therapeutics Expression Genes Genetic Tests GO Terms Pathways Publications Related Diseases Sources Summaries Symptoms Variations Top Bottom .", "label": "", "metadata": {}, "score": "95.00409"}
{"text": "Time to Deterioration ( TTD )[ Time Frame : From baseline through approximately month 10 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "95.04546"}
{"text": "Commitment to apoptosis was detected by immunocytochemistry against the apoptotic effector cleaved caspase-3 [ 75 ] ( Figure 4 A ) .This experiment revealed a gradual increase in the percentage of apoptotic cells , which became maximal at 48 hours ( Additional file 3 ) .", "label": "", "metadata": {}, "score": "95.47246"}
{"text": "Other forms of breast cancer begin in the glands that produce milk ( lobular cancer ) or in other parts of the breast .OMIM : 46 Breast cancer ( referring to mammary carcinoma , not mammary sarcoma ) is histopathologically and almost certainly ...", "label": "", "metadata": {}, "score": "96.00521"}
{"text": "- Director , Breast Cancer Research Baylor Charles A. Sammons Cancer Center Texas Oncology , PA / US Oncology , Dallas , Texas .Edith A. Perez , MD .", "label": "", "metadata": {}, "score": "97.464874"}
{"text": "Talk with your doctor and family members or friends about deciding to join a study .To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .", "label": "", "metadata": {}, "score": "97.79689"}
{"text": "Talk with your doctor and family members or friends about deciding to join a study .To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .", "label": "", "metadata": {}, "score": "97.79689"}
{"text": "SAN DIEGO -- Progression - free survival ( PFS ) in metastatic breast cancer doubled in women who received a new class of targeted therapy in addition to standard hormonal therapy , a randomized trial showed .", "label": "", "metadata": {}, "score": "98.17972"}
{"text": "Contacts ICMJE .Contact information is only displayed when the study is recruiting subjects .Listed Location Countries ICMJE .United States .Removed Location Countries .", "label": "", "metadata": {}, "score": "100.984"}
{"text": "In both arms , treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity .After completion of study treatment , patients are followed up every 6 months for 2 years and then annually for 3 years .", "label": "", "metadata": {}, "score": "101.26544"}
{"text": "Please use one of the following formats to cite this article in your essay , paper or report : .MLA American Association for Cancer Research .", "label": "", "metadata": {}, "score": "105.87399"}
{"text": "breast cancer kills more women in the united states than any cancer except lung cancer .no one knows why some women get breast cancer , but there are a number of risk factors .", "label": "", "metadata": {}, "score": "106.60806"}
{"text": "Signing up is FREE , FAST and SIMPLE .Begin by entering your email address below .Join tens of thousands of doctors , health professionals and patients who receive our newsletters .", "label": "", "metadata": {}, "score": "110.08711"}
{"text": "Professor of Medicine , Weill Cornell Cancer Center , Attending Physician at Memorial Sloan Kettering Cancer Center , New York , New York .The content contained in this video is for general information purposes only .", "label": "", "metadata": {}, "score": "110.360596"}
{"text": "Moderator Professor of Medicine , University of Pittsburgh Medical Director of the Women 's Cancer Center at Magee - Womens Hospital of UPMC and the University of Pittsburgh Cancer Institute Pittsburgh , Pennsylvania .", "label": "", "metadata": {}, "score": "111.85983"}
{"text": "\u00a9 2016 MedPage Today , LLC .All rights reserved .The material on this site is for informational purposes only , and is not a substitute for medical advice , diagnosis or treatment provided by a qualified health care provider .", "label": "", "metadata": {}, "score": "113.7338"}
{"text": "Left ventricular ejection fraction ( LVEF ) within institutional limits of normal .Gender .Female .Ages .18 Years and older .Accepts Healthy Volunteers .", "label": "", "metadata": {}, "score": "115.52219"}
{"text": "Copyright Medical News Today : Excluding email / sharing services explicitly offered on this website , material published on Medical News Today may not be reproduced , or distributed without the prior written permission of Medilexicon International Ltd.", "label": "", "metadata": {}, "score": "128.47908"}
{"text": "United States , Australia , Belgium , Canada , Germany , Ireland , Italy , Japan , Korea , Republic of , Netherlands , Portugal , Romania , Russian Federation , Taiwan , Turkey , Ukraine , United Kingdom", "label": "", "metadata": {}, "score": "131.34961"}
